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Persistent yellow fever endemicity and continued outbreaks have continued to increase vaccine 
demand, while straining global vaccine supply. Fractional dose vaccination is being considered as 
a dose-sparing strategy to mitigate current global vaccine shortages. This study therefore 
assessed the effects of fractional dose yellow fever vaccination, in comparison to those of the 
standard dose. We registered the review in the prospective register of systematic reviews; 
conducted a comprehensive search of published and grey literature; used standard Cochrane 
methods to collect and synthesise the evidence and followed the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) guidance. We stratified analyses by the 
strength of the fractional dose. We retrieved 2495 records from the literature search, nine of 
them potentially eligible. We included six eligible studies (three randomised and three quasi-
randomised trials), with 2371 participants. There was no statistically significant difference in 
immunogenicity between participants who received fractional doses containing one-third (two 
trials, 547 participants: RR 1.02, 95% CI 1.00 to 1.04; I2 = 0%), 1/5th (one trial, 155 participants: 
RR 1.00, 95% CI 0.98 to 1.03), 1/10th (four trials, 890 participants: RR 0.99, 95% CI 0.96 to 1.01, 
I2 = 0%), and 1/50th (three trials, 661 participants: RR 0.97, 95% CI 0.92 to 1.02, I2 = 72%) of the 
standard dose and those who received the full standard dose. However, immunogenicity was 
significantly lower among participants who received fractional doses containing 1/100th (four 
trials, 868 participants: RR 0.92, 95% CI 0.87 to 0.97, I2 = 60%) and <1/100th (five trials, 1053 
participants; RR 0.53, 95% CI 0.44 to 0.64, I2= 98%) of the standard dose compared to participants 
who received the full standard dose. Minor adverse events following vaccination did not differ 
across doses, but no serious adverse events were reported in any study arm. The combined data 
provide moderate certainty evidence that there is little or no difference in immunogenicity 
between ≥1/50th fractional doses and the standard dose of yellow fever vaccines. However, 
these studies were of short duration ranging from four weeks to a year. These findings support 
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Background: Persistent yellow fever endemicity and continued outbreaks have continued to 
increase vaccine demand, while straining limited global vaccine supply. To vaccinate susceptible 
populations in preventive mass-immunisation campaigns during outbreaks, fractional dose 
yellow fever vaccine is being considered as a dose-sparing strategy to maximise limited vaccine 
supplies. The purpose of this review is to assess the effects of this strategy in comparison with 
those of standard dose of the vaccine. 
Aims: This study aims to assess the effects (immunogenicity, efficacy, effectiveness or safety) of 
fractional-dose yellow fever vaccination in comparison to standard dose vaccination. 
Methods: We will conduct a comprehensive search of electronic databases and reference lists of 
relevant publications; and will follow the guidance contained in the statement on Preferred 
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). Studies that compared the 
effects and safety of fractional dose yellow fever vaccine with those of the standard dose vaccine 
will be included, regardless of study design. We will pool data using random-effects meta-
analyses. We will assess statistical heterogeneity using the Chi-squared test of homogeneity and 
quantify it using the Higgins’ I2 statistic. In the presence of statistically significant heterogeneity, 
we will conduct subgroup analyses, with subgroups defined by variations in study design, HIV 
status and region. 
Discussion: This review will provide a robust evidence-base for informing global health and 
vaccine policy and advocacy processes on the use of factional doses of vaccines as a dose-sparing 
strategy to mitigate vaccine shortages, while providing clinicians and immunisation programme 
stakeholders with a user-friendly evidence summary. It will also help to highlight remaining 
evidence and research gaps on fractional dose vaccination, to inform future research efforts. 
 





1.1. Description of the condition 
Yellow fever is a viral haemorrhagic disease of humans caused by the yellow fever virus.1 The 
disease mostly occurs in tropical areas of Africa and South America, where it is endemic and 
intermittently epidemic.1 2 The yellow fever virus is a prototypic member of the genus Flavivirus 
(flavus meaning yellow in Latin) having a relatively narrow host range, mostly humans and 
monkeys; and typically transmitted by Aedes mosquitoes.2 3 Globally, approximately 200 000 
cases of yellow fever and 30 000 deaths occur annually.4 5 Sub-Saharan Africa, where the disease 
remains a major global health concern, bears 90% of the disease burden.4 Typically, humans are 
infected when bitten by blood-feeding mosquitoes.2 Susceptibility to yellow fever depends on 
several factors, such as previous infection with the virus and other flaviviruses; immune status, 
environmental, racial and genetic factors.6 7 Transmission is largely dependent on availability of 
vector, vertebrate hosts and vegetation.8 
In humans, yellow fever disease can be asymptomatic or cause a wide spectrum of diseases, from 
mild symptoms to severe illness with fever, nausea, vomiting, hepatitis, jaundice and, in extreme 
cases, haemorrhagic shock and death.2 5 Case fatality ranges between 20 and 60%.9 There is no 
known cure or specific treatment for yellow fever, hence supportive treatment remains the 
mainstay of clinical management.2 Wild-type yellow fever infection can induce lifelong protection 
against subsequent infection.9 
Yellow fever poses a significant threat to unvaccinated persons travelling to endemic areas.10 
With globalisation and ease of international travel, there has been documented cases of human 
importation of the disease from endemic areas to places where it is non-endemic.10 Recently, 
imported cases have been reported in China, Kenya and Morocco.11 12 13 Due to transmission 
between non-human primates and mosquitoes, and by transovarial transmission in mosquitoes, 
eradication of the disease is extremely difficult.2 9 
The development of a life-attenuated yellow fever vaccine which came into use in 1938, and its 
wide roll-out in the 1940s, results in significant decline in the burden of disease.9 14 The World 
Health Organisation (WHO) recommends vaccination in high-risk countries, as part of the routine 
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childhood immunisation programmes as well as in mass immunisation campaigns during 
outbreaks.4 10 Additionally, vaccination is recommended for preventive immunisation of 
travellers to endemic regions, making yellow fever the only disease stipulated by international 
health regulations (IHR) for which proof of vaccination from travellers may be required by 
countries as a pre-condition for entry.4 
Yellow fever vaccine has been considered effective, immunogenic, safe and well tolerated.4 8 14-
17 There are numerous serological methods used to assess immune response. These include 
plaque reduction neutralisation, haemagglutination inhibition and complement fixation tests, as 
well as enzyme linked immunosorbent assay (ELISA) and indirect fluorescent antibody test.7 9 
Currently, detection and analysis of the immune response post-vaccination are mostly done using 
the plaque reduction neutralisation test 8 13, and is considered to be the most specific and gold-
standard method.4 
Adverse events following immunisation are classified based on severity as either non-serious or 
serious adverse events. The WHO classifies an adverse event as serious if it results in persistent 
or significant disability; a congenital anomaly or birth defect; intervention to prevent permanent 
impairment, hospitalisation or prolongation of hospitalisation; or death.18 Reported serious 
adverse events include anaphylactic or hypersensitivity reactions; Yellow fever vaccine-
associated viscerotropic disease which mimics naturally-acquired yellow fever disease and yellow 
fever vaccine-associated neurologic disease, which can manifest as meningoencephalitis, 
Guillain-Barré syndrome, or acute disseminated encephalomyelitis.18-21 The Brighton 
Collaboration case definitions provide a standardised classification of these serious adverse 
events using three distinct levels of diagnostic certainty, with levels 1, 2 and 3 representing the 
highest, intermediate and lowest levels of diagnostic certainty respectively.21-25 
Reporting rates for serious adverse events vary, due to differences in routes of vaccine 
administration, case definitions, study designs, surveillance methods, frequency of reporting, 
diagnostic capability and availability of other health-systems resources.26 27 Surveillance and 
adverse events monitoring during preventive vaccination campaigns in eight African countries 
showed low adverse events incidence attributable to underreporting and other structural 
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challenges. There were reports of non-adherence to standard criteria for assigning causality due 
to the unavailability of certain laboratory investigations, with the majority of reported events not 
meeting the Brighton case definitions. There were also reports of improper sample labeling, 
faulty containers, improper storage, and delays between collection and transport.27  
1.2. Description of the intervention 
Persistent endemicity and continued outbreaks have continued to increase vaccine demand, 
while straining limited global vaccine supply.4 13 Therefore, to vaccinate susceptible populations 
in preventive mass immunisation campaigns during outbreaks, fractional dosing of the vaccine is 
being considered as a dose-sparing strategy to maximise limited vaccine supplies.4 13 Fractional 
dose yellow fever vaccination refers to administration of a reduced volume of vaccine dose, 
which has been reconstituted as per manufacturer recommendations.4 The minimum potency 
recommended for standard dose should not be less than 1000 international units (IU)/dose.13 28 
However, the potency of standard doses is usually many-fold higher than the recommended 
potency.4 This forms the fundamental basis of fractional dose considerations. As a dose-sparing 
strategy, a fractional dose yellow fever vaccine meeting the minimum potency requirement is 
expected to be equivalent to a standard yellow fever vaccine dose with respect to safety, 
immunogenicity, efficacy and effectiveness.4 29 30 
The first practical use of fractional dose yellow fever vaccination was in response to a large yellow 
fever outbreak in the Democratic Republic of the Congo in mid-2016.4 13 This was to ensure that 
the entire target population could be vaccinated despite limited vaccine supply. The WHO 
International Coordinating Group  on vaccine coordinates the access to and provision of vaccines 
during outbreaks.4 It currently maintains a global emergency stockpile of six million doses of 
yellow fever vaccine, which is currently being threatened by increasing demands.13 31  
1.3. How the intervention might work 
Fractional dose vaccination against yellow fever works by stimulating humoral immunity through 
neutralising antibodies against the yellow fever virus.30 Various studies have investigated the 
protective effects and safety of fractional doses of the yellow fever vaccine in humans.29 30 32-38 
This review has systematically summarised the findings from these studies. 
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1.4. Why it is important to do this review 
We have found two non-systematic reviews of fractional dose yellow fever vaccination in the 
grey literature.13 28 However, we are unaware of any currently available comprehensive and 
systematic synthesis of the body of evidence on the effects and safety of this strategy, thus 
informing the need for this review. The use of meta-analysis in vaccinology has grown remarkably 
in recent years.39 It helps to produce quantitatively robust and accurate effect-size 
measurements that are generalisable.40 41 This review will add to the body of knowledge and fill 
knowledge gap, in addition to providing a robust evidence base for informing global health policy 
and advocacy processes for addressing vaccine shortages. Furthermore, the analytical rigour with 
which the review will be conducted will provide methodological guidance for subsequent 
reviews, while providing vaccinologists, clinicians, policy makers and other stakeholders a user-
friendly evidence summary. Current international best practices in the conduct of systematic 
reviews and meta-analyses will be followed; including registration on the International 
Prospective Register of Systematic Reviews (PROSPERO) 42 43 and design of this protocol in 
accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis 
Protocols (PRISMA-P) guidelines.44 
 
2. Objectives 
This review aims to assess the effects of fractional dose yellow fever vaccination, compared to 










3.1. Types of studies 
There will not be restriction on inclusion based on study-design; randomised trials, non-
randomised trails, and observational studies will be eligible for inclusion. 
3.2. Types of participants 
All individuals, irrespective of age will be included. 
3.3. Types of intervention 
The eligible intervention will be the administration of fractional doses of any live-attenuated 
yellow fever vaccine, while the eligible comparison will be the administration of the standard 
dose of the vaccine; irrespective of vaccination schedule, route of administration, or formulation. 
3.4. Types of outcome measures 
3.4.1. Primary outcomes 
• Immunogenicity i.e. levels of vaccine-specific virus-neutralising antibodies and rates of 
seroconversion, assessed at least four weeks following vaccination.45 
• Safety i.e. adverse events following vaccination as reported by authors and standardised 
using the WHO and the Brighton Collaboration case definitions.18-21 
3.4.2. Secondary 0utcomes 
• Incidence of laboratory-confirmed yellow fever cases9 46 
• Mortality 
3.5. Search methods 
A comprehensive electronic literature search will be conducted, from inception of each database 
to the date of the search. The following databases will be searched: Cochrane Library (including 
the Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of Abstracts of 
Reviews of Effects (DARE)), PubMed/Medline, EBSCOhost, Scopus, CINAHL, ClinicalTrials.gov, 
WHO International Clinical Trials Registry Platform (ICTRP), African Index Medicus, and Latin 
American and Caribbean Health Sciences Literature (LILACS). No language restrictions will be 
applied. The reference lists of relevant publications, including WHO position papers, will also be 
14 
 
searched for potentially eligible studies. The websites of WHO approved yellow fever vaccine 
manufacturers will also be searched. Additionally, relevant grey literature will be searched for 
relevant vaccination field reports, policy statements, and conference abstracts and proceedings. 
A provisional PubMed format search strategy is provided below (Table 1). It was developed with 
guidance from a reference librarian. The strategy will be adapted for other databases using 
appropriate controlled vocabulary and syntax. 
 




Search # Search Texts and Syntaxes 
#1 Yellow Fever [MeSH Terms] 
#2 Yellow Fever Vaccine [MeSH Terms] 
#3 yellow fever vaccine OR yellow fever vaccination OR yellow fever 
immunisation 
#4 #1 OR #2 OR #3 
#5 Dose-Response Relationship, Immunologic [MeSH Terms] 
#6 fractional dosing OR Fractionated dosing OR drug dose comparison OR sub-
dose OR sub-dosage OR reduced dose OR reduced dosing OR reduced dosage 
OR dose-sparing OR immunologic dose response relationship 
#7 #5 OR #6 
#8 safety OR adverse reaction OR adverse event OR adverse effects OR toxicity 
OR reactogenicity OR immunogenicity OR immunogenic OR immune response 
OR seroconversion OR efficacy OR effects OR effectiveness 
#9 #7 OR #8 
#10 #4 AND #9 
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The project team will be made up of four contributors: 
• Chukwudi A. Nnaji (CAN) will be the primary investigator. He will take lead in all aspects of 
the project and be the guarantor of the publication. 
• Muki S. Shey (MSS) will contribute to duplicate screening of search outputs, study selection, 
data extraction from included studies, and verification of data generated. He will provide 
immunological insights to the review and serve as a co-supervisor for this project. 
• Olatunji O. Adetokunboh (OOA) will contribute to duplicate screening of search outputs, 
study selection, data extraction from included studies, and verification of data generated. He 
will provide systematic review guidance to the primary investigator and serve as a co-
supervisor for this project. 
• Charles S. Wiysonge (CSW) will be a supervisor for this project and will be responsible for 
general guidance in conducting the review. He will arbitrate in cases where there are 
discrepancies in the independent assessment of eligibility and risk of bias or extracted data, 
that are not resolved through consensus. 
 
3.6. Data extraction and management 
Two researchers (CAN and either OOA or MSS) will independently screen the search output, to 
retrieve full texts of potentially eligible studies and assess their eligibility using predefined 
inclusion criteria. Disagreements in the eligibility assessment will be resolved through consensus 
between the two researchers and, if a consensus is not arrived at, CSW will arbitrate. If a study 
published in a language other than English is deemed eligible for inclusion, a translation will be 
sought.  
Following the selection of eligible studies, two researchers (CAN and either OOA or MSS) will 
independently extract relevant data using a standardised data extraction form. Study eligibility 
will be re-verified at the start of data extraction. Extracted data will include: 
• General details: authors’ details, affiliations, and year of publication. 
• Study details: design, setting, geographical location, risk of bias items  
• Participant characteristics: mean age and standard deviation, age range, sex, and sample size. 
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• Intervention details: vaccine sub-strain, strength of fractional dose, and route of 
administration 
• Outcome details: types of outcomes, outcome assessment methods, outcome data. 
Any disagreements between the two investigators will be resolved by discussion and, if a 
consensus is not arrived at, CSW will arbitrate. If required data are not available from study 
publications, CAN will contact the authors in an attempt to obtain the missing information. 
Extracted data will be entered by CAN into the analysis software, Review Manager 5.3.47 CSW will 
double-check the entered data for accuracy. 
3.7. Risk of bias assessment 
Two authors (CAN and either OOA or MSS) will independently assess each included study for risk 
of bias. For randomised trials, we  will use the seven specific domains of the Cochrane risk of bias 
tool.48 49  The seven domains include random sequence generation, allocation concealment, 
blinding of participants and personnel, blinding of outcome assessment, incomplete outcome 
data, selective outcome reporting, and other issues. For each included study, the two researchers 
will independently describe and make judgement of “low risk” of bias, “high risk” of bias, or 
“unclear risk” of bias accordingly. 
We will use the risk of bias in nonrandomised studies of interventions (ROBINS-I) tool for 
assessing risk of bias in non-randomised studies.50 The tool covers seven distinct domains for 
assessing risk of bias, including confounding; selection; intervention classification; deviations 
from intended interventions; missing data; measurement of outcomes; and selection of reported 
results. It categorises risk of bias judgements as “low risk”, “moderate risk”, “serious risk” and 
“critical risk” of bias; with “low risk” corresponding to the risk of bias in a high quality randomised 
trial. The two researchers will compare their independent risk of bias assessments and resolve 




3.8. Data analyses 
3.8.1. Measures of intervention effect 
We will analyse and report risk ratios (RR) with their corresponding 95% confidence intervals (CIs) 
for dichotomous data. For continuous outcomes, we will present mean differences (MD) with 
their corresponding 95% CIs.  
3.8.2. Dealing with missing data 
We will contact the corresponding authors to provide any unreported data relevant for analyses. 
If this does not yield a response, such unreported data will be classified as missing data and will 
be treated as such in the risk of bias assessment and analyses for the affected study. If the amount 
of incomplete outcome data is such that the trial is thought to be at a high risk of attrition bias, 
we will use imputation and perform sensitivity analyses to investigate the impact of the missing 
data.  
3.8.3. Data synthesis 
We will use the random-effects method to combine data from included studies, stratified by the 
strength of the fractional dose. We will assess statistical heterogeneity across included studies 
using the Chi-Squared test of homogeneity (with significance defined at the 10% α-level) and 
quantify it using the Higgins’ I2 statistic.48 51 Where meta-analysis is not appropriate, we will 
present narrative reports of findings. 
3.8.4. Subgroup analyses 
We will explore possible causes of significant statistical heterogeneity of effects by using 
subgroup analyses, with subgroups defined by study design (randomised versus non-
randomised), continent where study was conducted, and HIV status (positive versus negative). 
3.8.5. Sensitivity analyses 
We plan to perform sensitivity analyses for aspects of the review that could potentially affect the 
results, including high risk of bias and funnel plot asymmetry.  We will consider a randomised 
trial to have a high risk if there was no allocation concealment, no blinding of outcome assessors, 
or differential loss to follow-up in intervention arms of more than 25%. For non-randomised 
studies, the definition of high risk of bias will focus on selection of participants, missing data, and 
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measurement of outcomes. If we have evidence to suggest that small study effects are 
influencing the results of a meta-analysis, we will conduct sensitivity analyses to assess the 
robustness of the meta-analysis conclusions to different assumptions about the causes of funnel 
plot asymmetry. 
3.8.6. Assessment of reporting bias 
Funnel plots of estimated differences in outcome effects against their standard errors will be 
done if at least 10 studies are included in the meta-analysis. As a rule of thumb, funnel plot 
asymmetry should be used only when there are at least 10 studies included in the meta-analysis, 
because fewer studies will not have adequate power to distinguish chance from real 
asymmetry.48 
3.9. Grading the certainty of evidence 
We will use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
approach to assess the certainty of the evidence.52 We will generate GRADE evidence profiles 
and summary of findings tables for each primary outcome measure. 
4. Ethics and dissemination 
The planned systematic review will involve literature available through publicly accessible 
electronic databases, therefore research ethics review and approval are not required. We thus 
applied and obtained a waiver from the Human Research Ethics Committee of the University of 
Cape Town (#303/2018). 
5. Dissemination plans 
We will disseminate the findings of this review through Master’s Degree thesis for CAN, 
presentation at relevant scientific meetings, and publication in a peer-reviewed journal. 
6. Discussion 
The use of meta-analyses in vaccinology, in the context of systematic reviews, has grown 
remarkably in recent years.39 Meta-analyses help to produce quantitatively robust and accurate 
effect-size measurements that are generalisable.40 41 Although randomised studies, due to their 
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methodological rigour, help to contribute high quality to meta-analyses, the inclusion of other 
study designs allows meta-analyses to include relevant studies that have the potential to address 
the research question as comprehensively as possible. This poses the risk of introducing studies 
of low quality and compromising the certainty of the evidence generated from pooled estimates. 
The impacts can be addressed using the risk of bias appraisal, subgroup analyses defined by study 
designs as well as GRADE of evidence in the interpretation of pooled estimates. 
This review will add to the body of knowledge on the merits of fractional dose yellow fever 
vaccination. The analytical rigour with which the review will be conducted will provide 
methodological guidance for subsequent reviews, while providing vaccinologists, clinicians, 
policy makers and other stakeholders with a user-friendly evidence summary. 
7. Declaration of interests 
None. 
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1. Description of the condition 
1.1. Background 
Yellow fever is a viral haemorrhagic disease of humans caused by the yellow fever virus.1 The 
disease mostly occurs in tropical areas of Africa and South America, where it is endemic and 
intermittently epidemic.1 2 The yellow fever virus is a prototypic member of the genus Flavivirus 
(flavus meaning yellow in Latin) having a relatively narrow host range, mostly humans and 
monkeys; and typically transmitted by Aedes mosquitoes.2 3 Globally, approximately 200 000 
cases of yellow fever and 30 000 deaths occur annually. 4 5 Sub-Saharan Africa bears 90% of the 
disease burden.4 6 Typically, humans are infected when bitten by blood-feeding mosquitoes.2 
Susceptibility to yellow fever depends on several factors, such as previous infection with the virus 
and other flaviviruses; immune status; and environmental, racial and genetic factors.7 8 
Transmission is largely dependent on availability of vector, vertebrate hosts and vegetation.9 10 
1.2. Epidemiology of yellow fever 
1.2.1. Causative agent 
Yellow fever is caused by an arthropod vector-borne arbovirus from the flavivirus genus of the 
flaviviridae family. The virus is a prototype member of this genus. It is a positive-sense, single-
strand ribonucleic acid (RNA) virus 2, with a diameter of approximately 40 nm and 5 – 10 nm 
surface projections.11 Mature virions are icosahedral in shape and consist of a nucleocapsid, 
composed of capsid (C) protein subunits, surrounded by a lipid bilayer. The viral envelope is 
studded with membrane (M) protein and envelope (E) glycoproteins.11 12 The E glycoprotein is 
the major component of the virion surface and is involved in most of the biologic activity, 
including cell-surface receptor binding, fusion and immunogenicity.12 
1.2.2. Yellow fever vectors 
In Africa, the main vectors of yellow fever are mosquitoes of the genus Aedes, subgenera 
Stegomyia and Diceromyia with seven species: Aedes (Stegomyia) aegypti, A. (Stegomyia) 
africanus, A.(Stegomyia) opok, A. (Stegomyia) luteoceph alus, A. (Stegomyia) simpsoni group, A. 
(Diceromyia) furcifer, and A. (Diceromyia) taylori.13 Aedes mosquitoes are classified based on 
their mode of contact with humans. The domestic category consists mainly of A. aegypti; while 
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the semi-domestic category consists of wild vectors which can acquire domestic habits such as A. 
furcifer, A. africanus and A. luteocephalus.8 Monkeys and galagoes (bush babies) are the main 
vertebrate hosts. In savannah areas, these primates are exposed to mosquito bites and develop 
viraemia over a maximum period of nine days.12 13 The main vectors in South America are A. 
aegypti (urban) and A. Haemagogus (jungle).13 14 
1.2.3. Transmission of yellow fever 
The transmission of yellow fever is via two mechanisms; vertical and horizontal transmissions.8 
The less clear vertical mechanism of transmission occurs from orally infected females to their 
progeny.15 The horizontal mechanism consists of the maintenance and amplification cycles. 
Which of the two cycles prevails depends on the degree of contact with the susceptible host and 
the associated ecological factors.8 13 The maintenance cycle is the more stable cycle; it occurs 
when the vector-vertebrate contact is loose. This results in an endemic or enzootic form of yellow 
fever. In contrast, the amplification cycle results from closer vector–vertebrae contact and 
manifests in epizootic or epidemic forms of yellow fever. For transmission to occur, following a 
blood meal on an infected vertebrate host (e.g. monkeys or humans), the vector must remain 
alive long enough to allow full development and replication of the virus inside its tissues, and the 
virus must be inoculated with saliva into another vertebrate host during subsequent blood 
meals.8 
1.2.3.1. Transmission pattern in Africa 
In Africa, transmission patterns are largely dependent on the availability of invertebrate and 
vertebrate hosts, which are in turn determined by vegetation patterns.9 Currently, endemic 
regions in Africa can be found between latitudes 15 degrees north to 15 degrees south of the 
equator. Endemic forms of yellow fever occur year-round and transmission is primarily between 
monkeys and A. africanus.8 9 Due to the abundant presence of both vector and host populations, 
these areas are prone to high rates of sporadic outbreaks, particularly during the rainy seasons, 
when enzootic Aedes mosquitoes reach high densities.9 Urban-type transmission may also occur 
with resultant outbreaks of A. aegypti-borne yellow fever if the virus is introduced into urban 
regions by infected persons or mosquitoes.2 9 
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1.2.3.2. Transmission pattern in South America 
In South America, the transmission pattern consists of two cycles; jungle and urban.2 9 The jungle 
cycle is mainly transmitted by A. haemagogus, while the urban type is transmitted by A. aegypti. 
In this region, the disease mainly affects unvaccinated persons who enter the forest for hunting 
or wood cutting, making it an occupational disease.2 
1.2.3.3. Transmission pattern in Asia 
Despite the substantial presence of A. aegypti, the Asian region is not yellow fever endemic.2 14 
Some reasons have been postulated, including the likelihood of cross-protection between 
flaviviruses; absence of the maintenance cycle; and variation in vector competence and 
behaviour in the region.14 
1.2.3.4. Transmission among travelers 
Yellow fever poses a significant threat to unvaccinated persons travelling to endemic 
areas.11 With globalisation and ease of international travel, there have been documented cases 
of human importation of the disease from endemic areas to places where it is non-endemic.11 In 
2016, imported cases were reported in China 16 17 and Morocco.18 
1.2.4. Risk factors for acquiring and surviving yellow fever 
The susceptibility of individuals and populations to yellow fever depends on several factors. 
These include previous exposure to yellow fever and other flaviviruses; immune status; 
environmental; behavioural as well as racial and genetic factors.7 8 Population growth, increasing 
forest encroachment, migration, political unrest, wars and urbanisation all contribute to 
increased transmission.8 13 Previous infection and vaccination can confer life-long immunity.14 
Though an association between Human Leucocyte Antigen (HLA) haplotype and disease severity 
has been described 3, the role of genetic or racial factors in determining human host susceptibility 
to yellow fever infection remains uncertain.2 Lower rates of case fatalities have been 
demonstrated in blacks than in Caucasians.9 
1.2.5. Pathophysiology and clinical course 
Yellow fever in humans varies from a mild disease in which symptoms abate rapidly after the first 
phase, to an invariably fatal fulminating disease.11 Following inoculation, the virus replicates in 
the adjacent tissues and localised lymph nodes. An incubation period lasting 3-6 days is followed 
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by an abrupt onset of symptoms. In mild, abortive cases, symptoms are typically nonspecific; 
manifesting as fever, headache, and constitutional problems.2 12 In such cases, patients recover 
in a few days with no lasting sequelae. In severe cases, patients may experience nausea, fever, 
chills, malaise, headache, lower back pain, and generalised myalgia. Faget’s sign (increasing 
temperature with decreasing pulse rate) is also a common feature of severe cases.9 19 Severe 
disease can also manifest as pan-systemic viral sepsis; with pyrexia (which may be higher than 
39oC to 40oC); prostration; hepatic, renal, and myocardial injury; hemorrhage; shock; and fatality 
in 20 – 60% of cases.14 19  
1.2.6. Diagnosis and treatment 
Clinical diagnosis of yellow fever is based on the presence of sudden fever, relative bradycardia, 
and signs of jaundice in people in endemic areas or with history of recent travel to an endemic 
areas.11 19 The disease, however, shares clinical features with other viral haemorrhagic fevers 
such as the dengue hemorrhagic fever, Lassa fever, Ebola virus disease, and Crimean-Congo 
hemorrhagic fever. Hence, the risk of mis-diagnosis is high in sporadic or early epidemic cases.11 
14 Clinical diagnosis is further complicated by variations in symptomatic presentation. Mild cases 
are difficult to recognise. Laboratory diagnosis is therefore the definitive means of ascertaining 
cases. The laboratory criterion for diagnosis is at least one of the following: (1) the presence of 
yellow fever-specific Immunoglobulin M (IgM) or four-fold or more increase in Immunoglobulin 
G (IgG) levels between acute and convalescent sera in the absence of recent vaccination; (2) 
isolation of the virus; (3) positive postmortem liver histopathology; or (4) detection of viral 
antigen in tissues by immunohistochemistry or polymerase chain reaction.11 14 19 
There is no specific antiviral treatment for yellow fever.19 Passive antibodies such as interferons 
have been found to have very limited antiviral effect, and only useful before or within hours of 
infection and for prophylaxis following exposure in laboratory or health workers 11 14 19. 
Treatment is therefore primarily supportive.11 19 A standard treatment protocol comprises of 
maintenance of nutrition, rehydration, ventilation support, correction of metabolic imbalance, 
treatment of haemorrhage, dialysis if indicated by renal failure, and treatment of secondary 
infections. 19  
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1.2.7. Prevention of yellow fever through vector control 
Vector control is one of the two main methods of preventing yellow fever, the other method 
being vaccination.9 14 Vector control methods include community-based environmental 
interventions like spraying of breeding sites; biological methods involving the use of autocidal 
ovitraps, predatory toxorhynchite mosquitoes and predatory fishes; and individual-level 
measures consisting of the use of insect repellent, protective clothing and mosquito nets.14 
1.3. Global health importance of yellow fever and international health regulation (IHR) 
Quantifying the burden of yellow fever disease is made challenging by the wide spectrum of 
clinical severity and non-specificity of symptoms making diagnosis difficult. Additionally, there 
are limitations in the surveillance, diagnostic capacity and reporting across much of the affected 
regions, meaning that the disease is substantially underreported.20 Annual reporting of cases 
relies on passive surveillance and thus significantly underestimates the true incidence.2 It is, 
however, estimated that 200 000 cases of the disease and 30 000 deaths occur annually.4 5 Sub-
Saharan Africa bears approximately  90% of this burden.4 The disease poses an enormous health 
burden on residents in endemic regions, non-immunised travelers entering endemic areas and 
persons moving within their own country from low-risk to high-risk areas.21 
Dramatic upsurges in yellow fever outbreaks have occurred recently. These include Angola in 
2015, Democratic Republic of Congo and Uganda in 2016, and Nigeria and Brazil in 2017.4 18 22 
Imported cases were also reported in 2016 in China and Morocco.16 18 The underlying reasons for 
the increasing epidemics are multifactorial, involving vector density; viral virulence and 
emergence of new virus lineage; climatic factors such as increased rainfall and high 
temperatures; behavioural factors; and waning immunisation coverage.2 14 
Yellow fever is the only disease specified in the International Health Regulations (IHR) for which 
countries may require a proof of vaccination from travellers as a pre-condition for entry.4 The 
World Health Organisation (WHO) publishes and continually updates  a list of countries with risk 
of outbreaks and those requiring yellow fever vaccination as part of routine immunisation 
programme (see Figures 1 and 2 below).23 In practice, however, compliance with the IHR 
vaccination requirement is suboptimal.4 18 Compliance is made more challenging by porous 





Fig. 1: Yellow fever endemicity and vaccine requirement in Africa 24  
 
 
Fig. 2: Yellow fever endemicity and vaccine requirement in South America 24 
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1.4. Yellow fever vaccine 
The development of a life-attenuated yellow fever vaccine which came into use in 1938, and its 
wide roll-out, have led to significant decline in the burden of disease.14 25 Prevention through 
vaccination can limit the morbidity, mortality, and spread of outbreaks.14 26 The WHO strongly 
recommends vaccination in at-risk countries, as part of the routine childhood immunisation 
programmes. In addition to routine immunisation, preventive mass immunisation campaigns to 
prevent outbreaks, and reactive mass immunisation campaigns in response to outbreaks, yellow 
fever vaccination is used for preventive immunisation of travellers to endemic regions.4 11 
1.4.1. Yellow fever vaccine immunogenicity, efficacy and effectiveness 
The protective effects of vaccines can be measured through different types of studies.27-29 The 
measurement of a vaccine’s effect in randomised controlled studies is referred to as efficacy. 
Efficacy studies are however not commonly conducted due to the high cost of randomised 
studies as well as ethical concerns of withholding vaccines from participants in the placebo arms 
of studies. The measurement of a vaccine’s effect from observational studies is referred to as 
effectiveness. Immunogenicity refers to the ability of a vaccine to induce an immune response 
(antibody or cell-mediated) in vaccinated individuals.27  
Yellow fever vaccine is highly immunogenic, with results of clinical trials showing that 99% of 
vaccine recipients developed protective levels of neutralising antibodies within four weeks.4 9 13 
23 25 30 31 Until 2013, a booster-dose of the vaccine was recommended after 10 years.14 The 
concern for the tenth year booster was based on evidence of a time-dependent decrease in 
immunity, with one study showing that neutralising antibody titers decreased from 94% in the 
first year after vaccination to 75% ten years after.21  However, this recommendation for a booster 
has been challenged by many studies which suggest that the duration of immunity after 
vaccination may last for life in as many as 80% of those vaccinated.21 31 32 Moreover, it has been 
argued that even if there is some evidence that shows a decrease in neutralising antibodies over 
time, the proportion of the population with protective antibody titers at the end of the follow-
up period was consistently at the herd-immunity threshold of >60%.21 Consequently, in 2013, the 
WHO declared that booster vaccination was no longer necessary.33 34 
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There are numerous serological methods used to assess immune response following yellow fever 
vaccination. These include plaque reduction neutralisation, haemagglutination inhibition, 
complement fixation, enzyme linked immunosorbent assay, and indirect fluorescent antibody 
tests.8 14 Currently, detection and analysis of the immune response post-vaccination are mostly 
done using the plaque reduction neutralisation 9 18, which is considered to be the most specific 
and gold-standard method.4 Immunity in humans corresponds to 50–80% viral plaque 
reduction.35 
1.4.2. Safety of yellow fever vaccine 
Yellow fever vaccine has also been considered safe and well tolerated. Serious adverse events 
are rare.21 36 Reported serious adverse events include anaphylactic or hypersensitivity reactions; 
yellow fever vaccine-associated viscerotropic disease and yellow fever vaccine-associated 
neurologic disease.36-39 The mechanisms of these serious adverse events are poorly understood, 
though old age has been identified as a risk factor.40 41 The Brighton Collaboration case definitions 
provide a standardised classification of serious adverse events using three distinct levels of 
diagnostic certainty.39 42-45 Incidence of yellow fever vaccine-associated viscerotropic disease 
ranges from 0 to 0.21 cases per 100 000 vaccine doses in endemic regions, and from 0.09 to 0.40 
cases per 100 000 doses in non-endemic settings. Yellow fever vaccine-associated neurologic 
disease is estimated to occur at a frequency of 0.8 cases per 100 000 vaccine doses administered.4 
Reporting rates for serious adverse events can vary. Systematic reviews have found that such 
variation may be due to differences in routes of vaccine administration, case definitions, study 
designs, surveillance methods, frequency of reporting, diagnostic capability, and availability of 
other health-systems resources.46 47 The studies documented non-adherence to standard criteria 
for assigning causality due to the unavailability of certain laboratory investigations, with the 
majority of reported events not meeting the Brighton case definitions.46 47 There are also 
challenges with mis-classification of cases due to the similarities of serious adverse event 
symptoms with those of common conditions like malaria or bacterial meningitis. There were also 
reports of improper sample labeling, faulty containers, improper storage, and delays between 




2. Fractional dose yellow fever vaccination 
Fractional dose yellow fever vaccination refers to administration of a reduced volume of vaccine 
dose, which has been reconstituted as per manufacturer recommendations.4  Recent and 
ongoing yellow fever outbreaks are sharply increasing the demand for yellow fever vaccine, 
mounting enormous strain on the global stockpile and putting at risk the immunisation of 
endemic populations.4 48 Further compounding the global shortages is a global insufficient 
production capacity for the vaccine. Yellow fever vaccine is manufactured using a process that 
has not significantly and innovatively evolved for decades.26 49 Production capacity is limited by a 
combination of commercial and technical factors, including the uncertainty and commercial 
unattractiveness of the yellow fever vaccine market which limits the number of manufacturers 
and the amount of vaccine produced by each manufacturer. 49 Between 2001 and 2009, the total 
demand for yellow fever vaccine increased three-fold from 34 million to 105 million doses per 
year.18 49 Similarly, the list of countries with demand for the vaccine for routine immunisation 
increased from 33 to 44 within the same time frame.49 
The World Health Organisation’s International Coordinating Group (ICG) coordinates the supply 
of vaccines during outbreaks.4 It currently maintains a global emergency stockpile of six million 
doses of yellow fever vaccine, which is continually replenished.18 The stockpile was depleted three 
times during the 2016 outbreak and complicating this is the fact that current global yellow fever 
immunisation coverage is well below the 80% target expected to maintain herd immunity: with a recent 
study estimating that 43% of people living in high-risk settings remain unvaccinated.50 Therefore, to 
vaccinate susceptible populations in preventive mass immunisation campaigns during outbreaks, 
fractional dosing of the vaccine is being considered as a dose-sparing strategy to maximise limited 
supplies.4 18 
The first practical use of fractional doses during a mass vaccination campaign was in response to 
a large yellow fever outbreak in the Democratic Republic of Congo in 2016.4 18 The minimum 
potency as recommended by WHO for the standard dose of yellow fever vaccines should not be 
less than 1000 international units (IU) per dose.18 49 This forms the fundamental basis of fractional 
dose considerations, as the potency at release of the vaccine at standard doses is usually many-
fold higher than the recommended potency.4 As a dose-sparing strategy, a fractional dose 
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meeting the WHO minimum requirement for potency is expected to be equivalent to a standard 
dose of the vaccine with respect to safety, immunogenicity, efficacy and effectiveness.4 51 52 
 
3. How the fractional dose of yellow fever vaccine might work 
3.1. Protective effects of fractional dose yellow fever vaccine 
The protective immune response evoked by the administration of fractional doses of the yellow 
fever vaccine has been substantially investigated.51-58 The earliest study, a 1943 quasi-
randomised controlled trial conducted by Fox and colleagues involving 550 military personnel in 
Belo Horizonte, Brazil, found that as low as 1/100th fractional doses were able to produce 
seroconversion rates of >96% which were non-inferior to the standard (i.e. full) doses.56 This 
study is however limited by its demographically-restricted participants (exclusively male with no 
age-stratification), hence might not have been representative of the reference population from 
which their sample was drawn. The short follow-up duration of five weeks might also not have 
been adequate to account for possible differences in time-dependent immune responses. In their 
1977 trial involving 68 research laboratory staff in Beckenham and Dartford, England; Freestone 
and colleagues compared the protective immune responses between standard and <1/100th 
fractional doses. They found statistically significant lower immunogenicity of <1/100th fractional 
doses at four weeks post-vaccination.55 Though gender-inclusive, the study’s limitation however 
stems from its small sample size. A 1988 trial by Lopes and co-workers assessed seroconversion 
among 259 military personnel with eight different sub-doses in comparison to the standard dose 
of yellow fever vaccine 28 days after vaccination.54 They found that the inoculation of 200-500 
IU (much lower than the minimum required standard by WHO of 1,000 IU) of the vaccine induced 
seroconversion in 100% of participants. Only men were included in this trial, however, which 
might not have been representative of the reference population from which the study sample 
was drawn. Furthermore, the short follow-up duration of four weeks might not have been long 
enough to account for temporal differences in immune responses. 
In a 2008 randomised trial by Roukens and colleagues in Leiden, the Netherlands, 155 
participants who received 1/5th of the full dose of the vaccine were followed up for 1 year and 
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assessed for immunological responses.52 They demonstrated that from two weeks to one year 
after vaccination, neutralisation of viral plaques by 80% did not differ between participants who 
received fractional and standard doses. Sero-protection was reached in both intervention and 
comparison groups. The one-year follow-up duration of this study provides some evidence on 
the long-term protective immunity of fractional dose vaccination. The study is however limited 
by its sample size, lack of age-stratification of participants and the use of a modified plaque 
reduction neutralization test for assessing immune responses. The following year, Roukens and 
colleagues conducted another study to assess immune responses to reduced intradermal test-
dose of yellow fever vaccine in a small cohort of seven individuals with egg allergy. They found 
that intradermally administered 1/5th dose of the yellow fever vaccine sufficiently induced 
protective immune responses in all seven subjects. The study’s limitation however stems from 
its small sample size, lack of a comparison group, and involvement of only individuals with egg 
allergy.58 
More recently, a randomised trial conducted by Martins and colleagues in 2009, involving 749 
army recruits, in Rio de Janeiro, Brazil, found that 97% of participants who received as low as 
1/50th of the full dose achieved seroconversion at four weeks, similar to those who received the 
full dose.53 Participants were followed up for eight years, with 85.2% of them remaining 
seropositive; providing some evidence of prolonged protective immunity of fractional dose 
vaccination.59 The limitation of this study is its demographically-restricted sample, consisting 
exclusively of mostly young, male military personnel. Similarly, Campi-Azevedo and colleagues, 
in their 2014 trial conducted on 550 participants from the same cohort of participants as in the 
Martins et al study, similarly showed that as low as 1/50th of the standard dose was able to 
trigger comparable immunogenicity as the standard dose vaccine.51 The study was also 
demographically limited by age and gender of included participants. 
Most recently, Ahuka-Mundeke and colleagues conducted an observational study during the 
preventive immunisation campaign in response to the 2016 outbreak in the Democratic Republic 
of the Congo; to assess immune responses following fractional dose vaccination of 716 
individuals.57 They observed that 98% of participants who received the fractional dose had 
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seroconverted at 28 days of follow-up. Though the study had a relatively big sample size, it was 
limited by not having a control group of participants who received standard dose vaccination. 
Overall, these studies assessed the immunogenicity (antibody production and seroconversion 
rates) of fractional dose yellow fever vaccination at four to five weeks post-vaccination. Only one 
of the studies reported for a longer follow-up duration (one year).52 Immune response was 
assessed by the plaque reduction neutralisation test with seroconversion end-points defined at 
50 – 80% viral neutralisation51-54 56 or log10 neutralisation index of ≥0.7.55 Notably, most of the 
studies above were conducted in Latin America (Brazil)51 53 54 56 and Europe (England55 and the 
Netherlands52), with one conducted in Africa (Democratic Republic of Congo),57 indicative of a 
dearth of evidence on the African continent where the disease burden is enormous. 
3.2. Safety of fractional dose yellow fever vaccine 
The safety of fractional dose vaccination has been investigated.52 53 55 57 60 Local and systematic 
adverse events reported 0–10 days following fractional dose yellow fever vaccination included 
pain, hyperaemia, oedema, nausea, arthralgia, exanthema, and pruritus. In three of the studies 
that compared fractional and standard doses, there were no significant differences in the 
frequency of common non-serious adverse events.52 53 55 57 Observational studies by Nzolo and 
colleagues60 and Ahuka-Mundeke and colleagues57 have assessed the safety of the fractional 
dose vaccines administered in large cohorts of at-risk populations during mass preventive 
vaccination campaigns in response to the 2016 outbreak in Kinshasa, the densely populated 
capital city of the Democratic Republic of Congo. They did not observe any serious adverse effect 
following fractional dose yellow fever vaccination.4 18 Overall, none of the studies that assessed 
safety of fractional dose vaccination reported serious adverse events attributable to fractional 
dose vaccination; however, the sample sizes of the studies were not large enough and follow-up 
durations were not long enough to detect less common and serious adverse events. It is, 
therefore, hard to draw firm conclusions on the safety profile in terms of serious adverse event 
risks of fractional dose yellow fever vaccination.  
Though it has been argued that lower viral doses in vaccines might be associated with risk of 
vaccine-induced viraemia,61 49 however it has been shown that viraemia risk does not increase at 
lower vaccine doses.51 
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4. Why it is important to do this project 
We have found two non-systematic reviews of fractional dose yellow fever vaccination in the 
grey literature.18 49 However, we are not aware of any currently available comprehensive and 
systematic synthesis of the body of evidence on the effects of this strategy, thus informing the 
need for this review. None of the two grey literature documents provided a meta-analysis of the 
effects of fractional doses of yellow fever.  The small sample sizes of identified relevant primary 
studies and the dearth of larger single studies further justify the need for this review. The use of 
meta-analysis , which has grown remarkably in vaccinology in recent years, helps to produce 
quantitatively robust and accurate effect-size measurements that are generalizable.62-64 The 
planned systematic review will not only add to the body of existing knowledge, it will also fill a 
knowledge gap and provide a robust evidence base for informing relevant policy and advocacy 
processes. Current international best practices in the conduct of systematic reviews and meta-
analyses will be followed,  including prospective registration in the International Prospective 
Register of Systematic Reviews (PROSPERO) 65 66 and compliance with the Preferred Reporting 
Items for Systematic Review and Meta-analysis Protocols (PRISMA-P)67 and the Preferred 
Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines.68   
  
5. References   
1. Wiysonge CS, Nomo E, Mawo J, et al. Yellow fever control in Cameroon: where are we now and where 
are we going? BMC medicine 2008;6:3. doi: 10.1186/1741-7015-6-3 [published Online First: 
2008/02/12] 
2. Monath TP, Vasconcelos PF. Yellow fever. Journal of clinical virology : the official publication of the Pan 
American Society for Clinical Virology 2015;64:160-73. doi: 10.1016/j.jcv.2014.08.030 [published 
Online First: 2014/12/03] 
3. Barrett AD, Higgs S. Yellow fever: a disease that has yet to be conquered. Annual review of entomology 
2007;52:209-29. doi: 10.1146/annurev.ento.52.110405.091454 [published Online First: 
2006/08/18] 
4. World Health Organization (WHO). WHO position on the use of fractional doses - June 2017, addendum 
to vaccines and vaccination against yellow fever WHO: Position paper - June 2013. Vaccine 
2017;35(43):5751-52. doi: 10.1016/j.vaccine.2017.06.087 [published Online First: 2017/07/12] 
5. World Health Organization (WHO). Vaccines and vaccination against yellow fever: WHO Position Paper, 
June 2013--recommendations. Vaccine 2015;33(1):76-7. doi: 10.1016/j.vaccine.2014.05.040 
[published Online First: 2014/05/24] 




7. Gubler DJ. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? 
Comparative immunology, microbiology and infectious diseases 2004;27(5):319-30. doi: 
10.1016/j.cimid.2004.03.013 [published Online First: 2004/07/01] 
8. Casey G. Vaccines--how and why they work. Nursing New Zealand (Wellington, NZ : 1995) 
2016;22(1):20-4. [published Online First: 2016/04/05] 
9. Mutebi JP, Barrett AD. The epidemiology of yellow fever in Africa. Microbes and infection 
2002;4(14):1459-68. [published Online First: 2002/12/12] 
10. Chen LH, Hamer DH. Vaccination Challenges in Confronting the Resurgent Threat From Yellow Fever. 
JAMA: Journal of the American Medical Association 2017;318(17):1651-52. doi: 
10.1001/jama.2017.14258 
11. Gardner CL, Ryman KD. Yellow Fever: A Reemerging Threat. Clinics in laboratory medicine 
2010;30(1):237-60. doi: 10.1016/j.cll.2010.01.001 
12. Vasconcelos PF. [Yellow Fever]. Revista da Sociedade Brasileira de Medicina Tropical 2003;36(2):275-
93. [published Online First: 2003/06/14] 
13. Makhunga-Ramfolo N, Rheeder P. Safety and tolerability of yellow fever vaccines. Southern African 
Journal of Epidemiology and Infection 2012;27(1):16-18. doi: 10.1080/10158782.2012.11441474 
14. Barnett ED. Yellow fever: epidemiology and prevention. Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America 2007;44(6):850-6. doi: 10.1086/511869 
[published Online First: 2007/02/17] 
15. Diallo M, Thonnon J, Fontenille D. Vertical transmission of the yellow fever virus by Aedes aegypti 
(Diptera, Culicidae): dynamics of infection in F1 adult progeny of orally infected females. Am J 
Trop Med Hyg 2000;62(1):151-6. [published Online First: 2000/04/13] 
16. Dou XF, Zheng Y, Lyu YN, et al. [The first confirmed imported case of yellow fever in China]. Zhonghua 
liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi 2016;37(6):788-90. doi: 
10.3760/cma.j.issn.0254-6450.2016.06.009 [published Online First: 2016/06/28] 
17. Wilder-Smith A, Leong WY. Importation of yellow fever into China: assessing travel patterns. Journal 
of travel medicine 2017;24(4) doi: 10.1093/jtm/tax008 [published Online First: 2017/04/21] 
18. World Health Organization (WHO). Fractional Dose Yellow Fever Vaccine as a Dose-sparing Option for 
Outbreak Response. WHO Secretariat Information Paper. Department of Immunization, Vaccines 
and Biologicals. WHO reference number: WHO/YF/SAGE/16.1. Published  20 July 2016. Available 
via: http://apps.who.int/iris/bitstream/handle/10665/246236/WHO-YF-SAGE-16.1-
eng.pdf;jsessionid=F4BD11CEBB8426D52C781267F9795A8A?sequence=1 21 April 2018.  
19. Monath TP. Treatment of yellow fever. Antiviral research 2008;78(1):116-24. doi: 
10.1016/j.antiviral.2007.10.009 [published Online First: 2007/12/07] 
20. Garske T, Van Kerkhove MD, Yactayo S, et al. Yellow Fever in Africa: Estimating the Burden of Disease 
and Impact of Mass Vaccination from Outbreak and Serological Data. PLoS Medicine 
2014;11(5):e1001638. doi: 10.1371/journal.pmed.1001638 
21. Gotuzzo E, Yactayo S, Córdova E. Efficacy and Duration of Immunity after Yellow Fever Vaccination: 
Systematic Review on the Need for a Booster Every 10 Years. The American Journal of Tropical 
Medicine and Hygiene 2013;89(3):434-44. doi: 10.4269/ajtmh.13-0264 
22. Van den Broeck J, Eeckels R, Massa G. Maternal determinants of child survival in a rural African 
community. Int J Epidemiol 1996;25 doi: 10.1093/ije/25.5.998 
23. Becher H, Muller O, Jahn A, et al. Risk factors of infant and child mortality in rural Burkina Faso. Bull 
World Health Organ 2004;82 
24. Hobcraft J. Women's education, child welfare and child survival: a review of the evidence. Health 
Transit Rev 1993;3 
25. Norrby E. Yellow fever and Max Theiler: the only Nobel Prize for a virus vaccine. The Journal of 
Experimental Medicine 2007;204(12):2779. 
17 
 
26. Monath TP, Woodall JP, Gubler DJ, et al. Yellow fever vaccine supply: a possible solution. The 
Lancet;387(10028):1599-600. doi: 10.1016/S0140-6736(16)30195-7 
27. Banaszkiewicz A, Radzikowski A. Efficacy, effectiveness, immunogenicity - are not the same in 
vaccinology. World Journal of Gastroenterology : WJG 2013;19(41):7217-18. doi: 
10.3748/wjg.v19.i41.7217 
28. Weinberg GA, Szilagyi PG. Vaccine Epidemiology: Efficacy, Effectiveness, and the Translational 
Research Roadmap. The Journal of Infectious Diseases 2010;201(11):1607-10. doi: 
10.1086/652404 
29. Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety and effectiveness of 
pneumococcal conjugate vaccines (1998-2006). Vaccine 2007;25(12):2194-212. doi: 
10.1016/j.vaccine.2006.11.032 [published Online First: 2007/02/03] 
30. Shearer FM, Moyes CL, Pigott DM, et al. Global yellow fever vaccination coverage from 1970 to 2016: 
an adjusted retrospective analysis. The Lancet Infectious Diseases 2017;17(11):1209-17. doi: 
10.1016/S1473-3099(17)30419-X 
31. Groot H, Ribeiro RB. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years 
after vaccination with 17D vaccine. Bulletin of the World Health Organization 1962;27(6):699-707. 
32. Poland JD, Calisher CH, Monath TP, et al. Persistence of neutralizing antibody 30-35 years after 
immunization with 17D yellow fever vaccine. Bull World Health Organ 1981;59(6):895-900. 
[published Online First: 1981/01/01] 
33. World Health Organization (WHO). Yellow fever vaccination booster not needed. News Release. 17 
May 2013 Available via 
http://www.who.int/mediacentre/news/releases/2013/yellow_fever_20130517/en/ Accessed 
on 3 January 2018.  
34. WHO. Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013--
recommendations. Vaccine 2015;33(1):76-7. doi: 10.1016/j.vaccine.2014.05.040 [published 
Online First: 2014/05/24] 
35. Mercier-Delarue S, Durier C, Colin de Verdière N, et al. Screening test for neutralizing antibodies 
against yellow fever virus, based on a flavivirus pseudotype. PLoS ONE 2017;12(5):e0177882. doi: 
10.1371/journal.pone.0177882 
36. Thomas RE. Yellow fever vaccine-associated viscerotropic disease: current perspectives. Drug Design, 
Development and Therapy 2016;10:3345-53. doi: 10.2147/DDDT.S99600 
37. Thomas RE, Spragins W, Lorenzetti DL. How many published cases of serious adverse events after 
yellow fever vaccination meet Brighton Collaboration diagnostic criteria? Vaccine 
2013;31(52):6201-9. [published Online First: 2014/01/18] 
38. Thomas RE, Lorenzetti DL, Spragins W, et al. Active and passive surveillance of yellow fever vaccine 
17D or 17DD-associated serious adverse events: systematic review. Vaccine 2011;29(28):4544-55. 
doi: 10.1016/j.vaccine.2011.04.055 [published Online First: 2011/05/10] 
39. Rüggeberg JU, Gold MS, Bayas J-M, et al. Anaphylaxis: Case definition and guidelines for data 
collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5675-84. 
doi: https://doi.org/10.1016/j.vaccine.2007.02.064 
40. Roukens AH, Soonawala D, Joosten SA, et al. Elderly Subjects Have a Delayed Antibody Response and 
Prolonged Viraemia following Yellow Fever Vaccination: A Prospective Controlled Cohort Study. 
PLoS ONE 2011;6(12):e27753. doi: 10.1371/journal.pone.0027753 
41. Monath TP, Cetron MS, McCarthy K, et al. Yellow fever 17D vaccine safety and immunogenicity in the 
elderly. Human vaccines 2005;1(5):207-14. [published Online First: 2006/10/03] 
42. Lindsey NP, Rabe IB, Miller ER, et al. Adverse event reports following yellow fever vaccination, 2007–
13. Journal of travel medicine 2016;23(5):taw045-taw45. doi: 10.1093/jtm/taw045 
18 
 
43. Gershman MD, Staples JE, Bentsi-Enchill AD, et al. Viscerotropic disease: case definition and guidelines 
for collection, analysis, and presentation of immunization safety data. Vaccine 2012;30(33):5038-
58. doi: 10.1016/j.vaccine.2012.04.067 [published Online First: 2012/05/09] 
44. Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barre syndrome and Fisher syndrome: case definitions and 
guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 
2011;29(3):599-612. doi: 10.1016/j.vaccine.2010.06.003 [published Online First: 2010/07/06] 
45. Sejvar JJ, Kohl KS, Bilynsky R, et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis 
(ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization 
safety data. Vaccine 2007;25(31):5771-92. doi: 10.1016/j.vaccine.2007.04.060 [published Online 
First: 2007/06/16] 
46. Thomas RE, Lorenzetti DL, Spragins W, et al. Reporting rates of yellow fever vaccine 17D or 17DD-
associated serious adverse events in pharmacovigilance data bases: systematic review. Current 
drug safety 2011;6(3):145-54. [published Online First: 2011/11/30] 
47. Breugelmans JG, Lewis RF, Agbenu E, et al. Adverse events following yellow fever preventive 
vaccination campaigns in eight African countries from 2007 to 2010. Vaccine 2013;31(14):1819-
29. doi: 10.1016/j.vaccine.2013.01.054 [published Online First: 2013/02/12] 
48. World Health Organization (WHO). Fractional dose yellow fever vaccine as a dose-sparing option for 
outbreak response. WHO Secretariat information paper. World Health Organization Department 
of Immunization, Vaccines and Biologicals Geneva 2016;WHO/YF/SAGE/16.1(20 July 2016):76-7. 
doi: 10.1016/j.vaccine.2014.05.040 [published Online First: 2014/05/24] 
49. Hickling J, Jones R. Yellow fever vaccination: The potential of dose sparing to increase vaccine supply 
and availability. A Technical Programme Report for Programme for Appropriate Technology in 
Health (PATH) Report. 2013. Available via 
https://www.path.org/publications/files/TS_vtg_yf_rpt.pdf Accessed on 29 December 2017.  
50. Vannice K, Wilder-Smith A, Hombach J. Fractional-Dose Yellow Fever Vaccination — Advancing the 
Evidence Base. New England Journal of Medicine 2018;379(7):603-05. doi: 
10.1056/NEJMp1803433 
51. Campi-Azevedo AC, de Almeida Estevam P, Coelho-dos-Reis JG, et al. Subdoses of 17DD yellow fever 
vaccine elicit equivalent virological/immunological kinetics timeline. BMC Infectious Diseases 
2014;14:391-91. doi: 10.1186/1471-2334-14-391 
52. Roukens AH, Vossen AC, Bredenbeek PJ, et al. Intradermally Administered Yellow Fever Vaccine at 
Reduced Dose Induces a Protective Immune Response: A Randomized Controlled Non-Inferiority 
Trial. PLoS ONE 2008;3(4):e1993. doi: 10.1371/journal.pone.0001993 
53. Martins RM, Maia MdLS, Farias RHG, et al. 17DD yellow fever vaccine: A double blind, randomized 
clinical trial of immunogenicity and safety on a dose-response study. Human vaccines & 
immunotherapeutics 2013;9(4):879-88. doi: 10.4161/hv.22982 
54. Lopes Ode S, Guimaraes SS, de Carvalho R. Studies on yellow fever vaccine. III--Dose response in 
volunteers. Journal of biological standardization 1988;16(2):77-82. [published Online First: 
1988/04/01] 
55. Freestone DS, Ferris RD, Weinberg AL, et al. Stabilized 17D strain yellow fever vaccine: Dose response 
studies, clinical reactions and effects on hepatic function. Journal of biological standardization 
1977;5(3):181-86. doi: https://doi.org/10.1016/S0092-1157(77)80003-6 
56. Fox JP, Kossobudzki SL, Cunha JF. Field studies of the immune response to 17D yellow fever virus. Am 
J Hyg. 1943;38:113–38.  
57. Ahuka-Mundeke S, Casey RM, Harris JB, et al. Immunogenicity of Fractional-Dose Vaccine during a 
Yellow Fever Outbreak - Preliminary Report. The New England journal of medicine 2018 doi: 
10.1056/NEJMoa1710430 [published Online First: 2018/02/15] 
19 
 
58. Roukens AH, Vossen AC, van Dissel JT, et al. Reduced intradermal test dose of yellow fever vaccine 
induces protective immunity in individuals with egg allergy. Vaccine 2009;27(18):2408-9. doi: 
10.1016/j.vaccine.2009.02.049 [published Online First: 2009/04/17] 
59. de Menezes Martins R, Maia MLS, de Lima SMB, et al. Duration of post-vaccination immunity to yellow 
fever in volunteers eight years after a dose-response study. Vaccine 2018;36(28):4112-17. doi: 
10.1016/j.vaccine.2018.05.041 [published Online First: 2018/05/23] 
60. Nzolo D, Engo Biongo A, Lusakibanza M, et al. Safety profile of fractional dosing of yellow fever vaccine, 
experience from community based pharmacovigilance in Kinshasa, DRC2017. 
61. Sanchez V, Gimenez S, Tomlinson B, et al. Innate and adaptive cellular immunity in flavivirus-naive 
human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). 
Vaccine 2006;24(23):4914-26. doi: 10.1016/j.vaccine.2006.03.066 [published Online First: 
2006/04/25] 
62. Jacobson RM, Targonski PV, Poland GA. Meta-analyses in vaccinology. Vaccine 2007;25(16):3153-59. 
doi: https://doi.org/10.1016/j.vaccine.2007.01.047 
63. Lyman GH, Kuderer NM. The strengths and limitations of meta-analyses based on aggregate data. BMC 
Med Res Methodol 2005;5:14. doi: 10.1186/1471-2288-5-14 [published Online First: 2005/04/27] 
64. Nigeria Demographic and Health Survey, 2008. 2012, Ref Type: Online Source, 
[http://www.measuredhs.com/pubs/pdf/FR222/FR222.pdf]. 
65. Booth A, Clarke M, Dooley G, et al. The nuts and bolts of PROSPERO: an international prospective 
register of systematic reviews. Systematic Reviews 2012;1:2-2. doi: 10.1186/2046-4053-1-2 
66. Booth A, Clarke M, Ghersi D, et al. An international registry of systematic-review protocols. Lancet 
2011;377(9760):108-9. doi: 10.1016/s0140-6736(10)60903-8 [published Online First: 
2010/07/16] 
67. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-
analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ : British Medical Journal 
2015;349 doi: 10.1136/bmj.g7647 
68. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and 
meta-analyses of studies that evaluate health care interventions: explanation and elaboration. 





























Table of contents 
Abstract ........................................................................................................................................................ 3 
1. Background ............................................................................................................................................... 5 
1.1. Description of the condition ............................................................................................................. 5 
1.2. Description of the intervention ........................................................................................................ 6 
1.3. How the intervention might work .................................................................................................... 7 
1.4. Why it is important to do this review............................................................................................... 7 
2. Objectives ................................................................................................................................................. 8 
3. Methods .................................................................................................................................................... 8 
3.1. Types of studies ................................................................................................................................. 8 
3.2. Types of participants ......................................................................................................................... 8 
3.3. Types of intervention ........................................................................................................................ 8 
3.4. Types of outcome measures ............................................................................................................. 8 
3.5. Search methods ................................................................................................................................. 8 
3.6. Data extraction and management .................................................................................................... 9 
3.7. Risk of bias assessment ................................................................................................................... 10 
3.8. Data analyses................................................................................................................................... 10 
3.9. Grading the certainty of evidence .................................................................................................. 11 
4. Results..................................................................................................................................................... 12 
4.1. Literature search results and study selection ................................................................................ 12 
4.2. Description of included studies ...................................................................................................... 13 
4.3. Excluded studies .............................................................................................................................. 15 
4.4. Risk of bias in included studies ....................................................................................................... 16 
4.5. Measures of effect .......................................................................................................................... 17 
5. Discussion ............................................................................................................................................... 28 
6. Authors’ conclusions .............................................................................................................................. 31 
6.1. Implications for practice ................................................................................................................. 31 
6.2. Implications for future research ..................................................................................................... 32 





Background: Persistent yellow fever endemicity and continued outbreaks have continued to 
increase vaccine demand, while straining limited global vaccine supply. To vaccinate susceptible 
populations in preventive mass-immunisation campaigns during outbreaks, fractional dose 
yellow fever vaccine is being considered as a dose-sparing strategy to maximise limited vaccine 
supplies. 
Aim: This systematic review sought to assess the effects of fractional dose yellow fever 
vaccination in comparison with those of standard dose vaccination. 
Methods: We registered the review in the prospective register of systematic reviews (PROSPERO, 
number: CRD42018084214); conducted a comprehensive search of electronic databases and 
reference lists of relevant publications; and followed the guidance contained in the statement on 
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). We included 
randomised trials and quasi-randomised trials, expressed each study’s result as a risk ratio (RR) 
with its 95% confidence interval (CI), and pooled the data using the random-effects method. We 
stratified analyses by the strength of the fractional dose. We assessed statistical heterogeneity 
using the Chi-squared test of homogeneity and quantified it using the Higgins’ I2 statistic. 
Results: We retrieved 2495 records from the literature search, nine of them potentially eligible. 
We included six eligible studies (three randomised and three quasi-randomised trials), with 2371 
participants. There was no statistically significant difference in immunogenicity between 
participants who received fractional doses containing one-third (two trials, 547 participants: RR 
1.02, 95% CI 1.00 to 1.04; I2 = 0%), one-fifth (one trial, 155 participants: RR 1.00, 95% CI 0.98 to 
1.03), one-tenth (four trials, 890 participants: RR 0.99, 95% CI 0.96 to 1.01, I2 = 0%), and one-
fiftieth (three trials, 661 participants: RR 0.97, 95% CI 0.92 to 1.02, I2 = 72%) of the standard dose 
and those who received the full standard dose. However, immunogenicity was significantly lower 
among participants who received fractional doses containing 1/100th (four trials, 868 
participants: RR 0.92, 95% CI 0.87 to 0.97, I2 = 60%) and <1/100th (five trials, 1053 participants; 
RR 0.53, 95% CI 0.44 to 0.64, I2= 98%) of the standard dose than among those who received the 
full standard dose. Minor adverse events following vaccination did not differ across doses, but 
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no serious adverse events were reported in any study arm. The combined data provide moderate 
certainty evidence that there is little or no difference in immunogenicity between ≥1/50th 
fractional doses and the standard dose of yellow fever vaccines. However, due to limited data, 
we are uncertain whether there are differences between standard and fractional doses of yellow 
fever vaccines in the incidence of severe adverse events following vaccination. 
 
Conclusion: These findings of this review support the use of fractional dose yellow fever 
vaccination as a dose-sparing strategy for yellow fever vaccination. 
 


















Yellow fever is a viral haemorrhagic disease of humans caused by the yellow fever virus.1 The 
disease mostly occurs in tropical areas of Africa and South America, where it is endemic and 
intermittently epidemic.1 2 The yellow fever virus is a prototypic member of the genus Flavivirus 
(flavus meaning yellow in Latin) having a relatively narrow host range, mostly humans and 
monkeys; and typically transmitted by Aedes mosquitoes.2 3 Globally, approximately 200 000 
cases of yellow fever and 30 000 deaths occur annually. 4 5 Sub-Saharan Africa, where the disease 
remains a major global health concern, bears 90% of the disease burden.4 6 Typically, humans are 
infected when bitten by blood-feeding mosquitoes.2 Susceptibility to yellow fever depends on 
several factors, such as previous infection with the virus and other flaviviruses; immune status; 
and environmental, racial and genetic factors.7 8 Transmission is largely dependent on availability 
of vector, vertebrate hosts and vegetation.9 10 
 
1.1. Description of the condition 
In humans, yellow fever disease can be asymptomatic or cause a wide spectrum of diseases, from 
mild symptoms to severe illness with fever, nausea, vomiting, hepatitis, jaundice and, in extreme 
cases, haemorrhagic shock and death.2 5 11 Case fatality ranges from 20 to 60%.12 There is no 
known cure or specific treatment for yellow fever, hence supportive treatment remains the 
mainstay of clinical management.2 Wild-type yellow fever infection can induce lifelong protection 
against subsequent infection.12 
Yellow fever poses significant threat to unvaccinated persons travelling to endemic areas,13 and 
with globalisation and ease of international travel, there has been documented cases of human 
importation of the disease from endemic areas to places where it is non-endemic.13 Recently, 
imported cases have been reported in China, Kenya and Morocco.14 15 16 Due to transmission 
between non-human primates and mosquitoes, and by transovarial transmission in mosquitoes, 
eradication of the disease is extremely difficult.2 9 
The development of a life-attenuated vaccine which came into use in 1938, and its wide roll-out 
in the 1940s, have resulted in significant decline in the burden of yellow fever disease.12 17 The 
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World Health Organisation (WHO) recommends vaccination in at-risk countries, as part of the 
routine childhood immunisation programmes as well as in mass immunisation campaigns during 
outbreaks.4 13 Additionally, vaccination is recommended for preventive immunisation of 
travellers to endemic regions.4 Yellow fever vaccine has been considered highly immunogenic, 
with results of clinical trials showing that 99% of vaccine recipients developed protective levels 
of neutralising antibodies within four weeks.4 9 17-21 Currently, the plaque reduction neutralisation 
test is considered to be the gold-standard serological method for assessing immune response to 
yellow fever vaccination.9 16 
Yellow fever vaccine has also been considered safe and well tolerated. Serious adverse events 
are rare.22 23 Reported serious adverse events include anaphylactic or hypersensitivity reactions; 
yellow fever vaccine-associated viscerotropic disease and yellow fever vaccine-associated 
neurologic disease.22 24-26 The mechanisms of these serious adverse events are poorly 
understood, though older age has been identified as a risk factor.27 28 The Brighton Collaboration 
case definitions provide a standardised classification of serious adverse events using three 
distinct levels of diagnostic certainty.26 29-32 Incidence of yellow fever vaccine-associated 
viscerotropic ranges from 0 to 0.21 cases per 100 000 vaccine doses in endemic regions, and from 
0.09 to 0.4 cases per 100 000 doses in non-endemic settings. Yellow fever vaccine-associated 
neurologic disease is estimated to occur at a frequency of 0.8 cases per 100 000 vaccine doses 
administered.4 
 
1.2. Description of the intervention 
Persistent endemicity and continued outbreaks have continued to increase vaccine demand, 
while straining limited global supplies.4 16 Therefore, to vaccinate susceptible populations in 
preventive mass immunisation campaigns during outbreaks, fractional dosing of the vaccine is 
being considered as a dose-sparing strategy to maximise limited supplies.4 16 Fractional dose 
yellow fever vaccination refers to administration of a reduced volume of vaccine dose, which has 
been reconstituted as per manufacturer recommendations.4 While, the minimum potency 
recommended for standard dose should not be less than 1000 international units (IU)/dose,16 33 
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the potency of standard doses is usually many-fold higher than recommended.4 This forms the 
fundamental basis of fractional dose considerations. As a dose-sparing strategy, a fractional dose 
of the yellow fever vaccine meeting the minimum potency requirement is expected to be 
equivalent to a standard yellow fever vaccine dose with respect to safety, immunogenicity, 
efficacy and effectiveness. 4 34 35 The first practical use of fractional doses was in response to a 
large yellow fever outbreak in the Democratic Republic of the Congo in mid-2016.4 16 
 
1.3. How the intervention might work 
Fractional dose vaccination against yellow fever works by stimulating humoral immunity through 
neutralising antibodies against the yellow fever virus.35 Various studies have investigated the 
protective effects and safety of fractional doses of the yellow fever vaccine in humans.34-42 This 
review has systematically summarised the findings from these studies. 
 
1.4. Why it is important to do this review 
We have found two non-systematic reviews of fractional dose yellow fever vaccination in the 
grey literature.16 33 However, we are unaware of any currently available comprehensive and 
systematic synthesis of the body of evidence on the effects and safety of this strategy, thus 
informing the need for this review. Also, the use of meta-analysis in vaccinology has grown 
remarkably in recent years;43 helping to produce quantitatively robust and accurate effect-size 
measurements that are generalisable.44 45 Therefore, this review will not only add to the body of 
knowledge and fill knowledge gap, it will provide a robust evidence-base for informing global 
health and vaccine policy and advocacy processes. Furthermore, the analytical rigour with which 
the review was conducted will provide methodological guidance for subsequent reviews, while 
providing vaccinologists, clinicians and policy makers a user-friendly evidence summary. 
Current international best practices in the conduct of systematic reviews and meta-analyses were 
followed; including registration on the International Prospective Register of Systematic Reviews 
(PROSPERO) 46 47 and synthesised the evidence in accordance with the Preferred Reporting Items 




To assess the effects of fractional dose yellow fever vaccination, compared to vaccination using 
the standard dose of the vaccine. 
3. Methods 
3.1. Types of studies 
There was no restriction on inclusion based on study-design. 
3.2. Types of participants 
All individuals, irrespective of age were eligible for inclusion. 
3.3. Types of intervention 
The eligible intervention was the administration of fractional doses of the live-attenuated yellow 
fever vaccine, while the eligible comparison was the administration of the standard dose of the 
vaccine; irrespective of vaccination schedule, route of administration or formulation. 
3.4. Types of outcome measures 
3.4.1. Primary outcomes 
• Immunogenicity: i.e. levels of vaccine-specific virus-neutralising antibodies and rates of 
seroconversion, assessed at least four weeks following vaccination.49 
• Safety i.e. adverse events following vaccination as reported by authors and standardised 
using the WHO and the Brighton Collaboration case definitions.22 24-26 
 
3.4.2. Secondary 0utcomes 
• Incidence of laboratory-confirmed yellow fever cases12 50 
• Mortality 
 
3.5. Search methods 
We conducted a comprehensive search of peer-reviewed literature in multiple electronic 
databases from inception of each database to the date of the search. Search strategies (see 
Appendix 1) were developed with guidance from a reference librarian and adapted for the 
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various databases using appropriate controlled vocabulary and syntax. The following databases 
were searched: Cochrane Library (including the Cochrane Central Register of Controlled Trials 
(CENTRAL) and the Database of Abstracts of Reviews of Effects (DARE)), PubMed/Medline, 
EBSCOhost, Scopus, Cumulative Index of Nursing and Allied Health (CINAHL), ClinicalTrials.gov, 
WHO International Clinical Trials Registry Platform (ICTRP), African Index Medicus, and Latin 
American and Caribbean Health Sciences Literature (LILACS). Additionally, we conducted a hand 
search of reference lists of relevant studies and grey literature, including vaccine-related journals 
and WHO position papers, relevant vaccination field reports, policy statements and conference 
abstracts and proceedings. 
Two researchers (Chukwudi A. Nnaji (CAN) and either Muki S. Shey (MSS) or Olatunji O. 
Adetokunboh (OOA)) independently screened the search output, to retrieve full texts of 
potentially eligible studies and assess their eligibility using predefined inclusion criteria. 
Disagreements in the eligibility assessment were resolved through consensus between the two 
researchers.  If there was no consensus following discussion, Charles S. Wiysonge (CSW) would 
have arbitrated. 
 
3.6. Data extraction and management 
Following the selection of eligible studies, two researchers (CAN and OOA or MSS) independently 
extracted relevant data using a standardised data extraction form (see Appendix 2). We re-
verified study eligibility at the start of data extraction. 
Extracted data included: 
• General details: authors’ details, affiliations and year of publication. 
• Study details: design, setting, geographical location and risk of bias items 
• Participant characteristics: mean age and standard deviation, age range, sex, ethnicity and 
sample size. 
• Intervention details: vaccine sub-strain, strength pf fractional dose and route of 
administration 
• Outcome details: types of outcomes, outcome assessment methods, outcome data. 
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Disagreements between the two investigators were resolved by discussion. If a consensus was 
not arrived at, CSW would have arbitrated. If required data were not available from study 
publications, CAN would have contacted the authors to obtain the missing information. Extracted 
data were entered by CAN into the Cochrane meta-analytical software.51 CSW double-checked 
the entered data for accuracy. 
 
3.7. Risk of bias assessment 
Two researchers (CAN and either OOA or MSS) independently assessed each included study for 
risk of bias using the seven specific domains of the risk of bias tool, as described in the Cochrane 
Handbook for Systematic Reviews of Interventions.52 53 The seven domains included random 
sequence generation, allocation concealment, blinding of participants and personnel, blinding of 
outcome assessment, incomplete outcome data, selective outcome reporting and other bias. We 
assessed the adequacy of random sequence generation and allocation concealment for risk of 
selection bias; and blinding of participants and personnel for the risk of performance bias.  For 
the risk of detection bias, we assessed the blinding of outcome assessors, and completeness of 
outcome data and outcome reporting for the risks of attrition and reporting biases, respectively. 
For each domain, we classified the risk of bias as low if the criterion was adequately addressed, 
high if not adequately addressed, and unclear if the information provided was insufficient or 
unavailable to make an informed judgement. We summarised the assessment and categorised 
each included study either as having a low or a high risk of bias. Any study that had a high risk of 
selection, detection or attrition bias was categorised as having a high risk of bias. All other studies 
were considered to have a low risk of bias. 
3.8. Data analyses 
3.8.1. Measures of effects 
We analysed and reported risk ratios (RR) with their corresponding 95% confidence intervals (CI) 
for dichotomous data.  
3.8.2. Dealing with missing data 




3.8.3. Data synthesis 
We used the random-effects method to combine data from included studies and stratified by the 
strength of the fractional dose. We assessed statistical heterogeneity across included studies 
using the Chi-Squared test of homogeneity (with significance defined at the 10% α-level) and 
quantify it using the Higgins’ I2 statistic.52 54 
 
3.8.4. Subgroup analyses 
We conducted subgroup analyses to explore possible causes of significant statistical 
heterogeneity of effects, with subgroups defined by vaccine sub-strain and continent where 
study was conducted. 
3.8.5. Sensitivity analyses 
We performed sensitivity analyses to assess the robustness of pooled estimates to risk of bias. 
 
3.8.6. Assessment of reporting bias 
We could have performed funnel plot of estimated differences in outcome effects against their 
standard errors if there were at least 10 studies included in the review, as required for the 
assessment of publication bias.52 We however minimised the potential for reporting bias by 
conducting a comprehensive search of both published and grey literature. 
 
3.9. Grading the certainty of evidence 
We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
approach to assess the certainty of the evidence on the effect of fractional dosing of yellow fever 





4.1. Literature search results and study selection 
The literature searches generated a total of 2494 records. After screening titles and abstracts of 
the records, we discarded 2486 clearly irrelevant records. An additional study was found through 
hand search of the reference lists of included studies. Of the nine potentially eligible studies, six 
met the study’s inclusion criteria.34-39 The remaining three were excluded for not having control 





















Figure 1: PRISMA flow diagram showing study selection process   
Records identified through database 
searching 




























Additional records identified through 
other sources 
(n = 1) 
Records after duplicates removed 
(n = 2495) 
Records screened 
(n = 2495) 
Records excluded 
(n = 2486) 
Full-text articles assessed 
for eligibility 
(n = 9) 
Full-text articles excluded 
(n = 3); 
No control groups (n = 3) 
Studies included in 
qualitative synthesis 
(n = 6) 
Studies included in quantitative 
synthesis (meta-analysis) 
(n = 6) 
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4.2. Description of included studies 
Of the six included studies, three are randomised controlled trials34-36, while the others are quasi-
randomised trials.37-39 Table 1 below summarises the characteristics of the six included studies. 
A total of 2371 participants participated in the studies, with individual study sample sizes ranging 
from 68 to 749. Four of the studies were conducted in Latin America (Brazil)34 36 37 39, while two 
were undertaken in Europe (England38 and the Netherlands35). In terms of settings, four of the 
studies were conducted in military settings34 36 37 39 and the other two involved civilian 
participants.35 38 In all studies, participant were healthy adults, with reported age ranging from 
18 to 59 years. 
The 17D sub-strain yellow fever vaccine was administered in four studies35 37-39, whereas the 
17DD sub-strain was used in the other two.34 36 Fractional doses with which comparison was 
made with their corresponding reference standard (or undiluted) doses varied by strength of 
dilution as well as units of vaccine doses across studies and their respective intervention arms. 
Fox 1943 compared standard doses with fractional doses corresponding to 1/10th; 1/100th; and 
<1/100th of the reference standard dose39; Freestone 1977 did comparison with dilution 
strengths of <1/100th38; Lopes 1988 used dilutions corresponding to 1/10th, 1/50th, 1/100th and 
<1/100th37; Roukens 2008 used 1/5th (0.1mL) of the reference standard dose35; while Martins 
2013 and Campi-Azevedo 2014 used fractional doses corresponding to 1/3rd, 1/10th, 1/50th, 
1/100th and <1/100th of the reference standard dose.34 36 All studies assessed immunogenicity 
with seroconversion rates across vaccination arms. Actual antibody geometric mean titre values 
were reported in three studies.34 36 37 Immune response was assessed by the plaque reduction 
neutralisation test with seroconversion end-points defined at 50 – 80% viral neutralisation34-37 39 





Table 1: Characteristics of included studies 
Study  Design Participants Interventions and comparisons Outcome assessment methods 
Fox 1943 qRCT 550 military 
personnel 
 







Intervention: vaccination with 
five dilutions of the 17D YF 
vaccine; 1/10; 1/100; 1/1000; 
1/10 000 and 1/100 000 
 
Comparison: vaccination with 
standard (undiluted) dose of 
the 17D yellow fever vaccine. 
Seroconversion: determined by a 50% viral 
plaque reduction by anti-YF neutralising 
antibody titres five weeks following 
vaccination using the plaque reduction and 
neutralisation test (PRNT). 
 
Antibody Geometric Mean Titre (GMT): not 
reported 
 



















Intervention: vaccination with 
five sub-doses of stabilised 17D 
YF vaccine; 10 5.26 (181 970) 
PFU; 10 5.27 (186 209) PFU; 10 
2.25 (178) PFU; 10 1.49 (31) PFU 
and 10 0.98 (10) PFU 
 
Comparison: vaccination with 
unstabilised standard dose of 
the 17D yellow fever vaccine; 10 
5.26 (181 970) PFU vaccine. 
Seroconversion: determined by viral plaque 
reduction by anti-yellow fever neutralising 
antibody titres four weeks following 
vaccination using the PRNT. 
 
Antibody GMT: not reported. Instead, mean 
antibody response was reported and 
expressed as neutralising index. 
 
Safety: self-reported adverse events by 
volunteers, who were instructed to fill out a 
diary for adverse events during the first 8 
days after vaccination. 
 





Sex: all male 
 
Age range 
(mean): 18 – 47 
(21.6) years 
 
Location: Rio de 
Janeiro, Brazil 
Intervention: vaccination with 
four diluted doses of the 17D 
yellow fever vaccine (1/10th, 
1/60th, 1/100th and 1/1000th 
dilutions) 
 
Comparison: vaccination with 
full dose (>1656 PFU) of the 17D 
yellow fever vaccine 
Seroconversion: determined by a 50% viral 
plaque reduction by anti-yellow fever 
neutralising antibody titres four weeks 
following vaccination using PRNT. 
 
Antibody GMT: expressed in PFU/dose 
 






from a university 
 










Intervention: vaccination with 
fractional dose (0.1mL) dose of 
the 17D yellow fever vaccine 
administered intradermally. 
 
Comparison: vaccination with 
standard dose (0.5mL) of the 
17D yellow fever vaccine 
administered subcutaneously. 
Seroconversion: for comparison of standard 
and fractional vaccinations, serum dilution 
at which 80% viral neutralisation occurred 
was taken as endpoint at two, four and eight 
weeks and 1 year after vaccination using 
modified PRNT. 
  
Antibody GMT: not reported. 
 
Safety: participants reported duration and 
severity of adverse events after vaccination 
in a three-week diary. Safety of vaccination 
expressed in various parameters, number of 
15 
 
days events lasted and severity of event 
(absent, mild, moderate and severe). 





Sex: all male 
 
Mean age: 18 – 
30 (19.4) years 
 
Location: Rio de 
Janeiro, Brazil 
Intervention: vaccination with 
5 sub-doses of the 17DD yellow 
fever vaccine 10,447 IU, 3,013 
IU, 587 IU, 158 IU and 31 IU 
 
Comparison: vaccination with 
standard dose (27,476 IU) of the 
17DD yellow fever vaccine 
Seroconversion: determined by a 50% viral 
plaque reduction by anti-yellow fever 
neutralising antibody titres at 30 days 
(approximately four weeks) and 10 months 
following vaccination using PRNT. 
 
Antibody GMT: expressed in log10 mIU/mL 
and 2.7 log10 mIU/mL as the cut-off point to 
segregate seropositive from seronegative 
samples. 
 
Safety: volunteers filled out an adverse 
events diary during the first 10 days after 
vaccination. Intensity of adverse events 
were evaluated on a scale from 0 to 4, 











Sex: all male 
 
Mean age: 19 
years (age range 
not described) 
 
Location: Rio de 
Janeiro, Brazil 
Intervention: vaccination with 
5 sub-doses of the 17DD yellow 
fever vaccine 10,447 IU, 3,013 
IU, 587 IU, 158 IU and 31 IU. 
 
Comparison: vaccination with 
standard dose (27,476 IU) of the 
17DD yellow fever vaccine. 
Seroconversion: determined by a 50% viral 
plaque reduction by anti-yellow fever 
neutralising antibody titres at 26 - 34 days 
(approximately four weeks) following 
vaccination using the plaque reduction and 
neutralisation test (PRNT). Serology was 
conducted on 885 paired samples from 590 
participants. 
 
Antibody GMT: assessed in log10 mIU/mL 
but not expressed in actual numeric figures. 
 
Safety: not assessed. 
RCT: randomised controlled trial; qRCT: quasi-randomised controlled trial. 
 
4.3. Excluded studies 
We excluded three studies for not having comparison groups; Roukens 2009 41, Nzolo 201740, and 
Ahuka-Mundeke 201842. Roukens 2009 was a cohort study that assessed immune response to 
reduced intradermal doses of the yellow fever vaccine in individuals with egg allergy and the 
other two studies assessed the immunogenicity and safety of fractional dose vaccination during 
a mass preventive vaccination campaign. In the appendix, a table of characteristics of excluded 




4.4. Risk of bias in included studies 
One randomised trial had adequate random sequence generation and allocation concealment.35 
Of the other five studies, one had a high risk of selection bias due to inadequate random 
sequence generation and allocation concealment37, while the risk was unclear in the rest.34 36 38 
39 Two studies had a low risk of bias for blinding of participants and personnel.35 36 Outcome 
assessors were not aware of intervention allocations in one study36, but this was not the case in 
the remaining five.34 35 37-39 One study had a high risk of attrition bias (loss to follow-up and post-
randomisation exclusion of  >25% with attrition imbalance across arms)34, while the rest had a 
low risk of attrition bias.  All studies had a low risk of selective outcome reporting37, while one 
had an unclear risk of other biases.37 Table 2 shows a summary of the risk of bias in included 
studies. 
Table 2: Summary of risk of bias in included studies. 
 Fox 1943 Freestone 
1977 






Random sequence generation (selection bias) 
      
Allocation concealment (selection bias) 
      
Blinding of participants and personnel 
(performance bias)       
Blinding of outcome assessment (detection bias) 
      
Incomplete outcome data (attrition bias) 
      
Selective reporting (reporting bias) 
      
Other bias 
      













4.5. Measures of effect 
4.5.1. Immunogenicity 
4.5.1.1. Seroconversion rates in individual studies 
Table 3 below describes the immunogenicity in each study according to their respective vaccine 
arms. In the earliest study by Fox and colleagues in 1943, Belo Horizonte, Brazil; 109 army recruits 
were vaccinated with standard doses of the 17D yellow fever vaccine, while 116, 103 and 222 
others received 1/10th, 1/100th and <1/100th fractional doses of the reference vaccine 
respectively. Seroconversion rates (proportions of vaccinated participants who seroconverted at 
five weeks following vaccination) were found to be 100% (109/109), 98.28% (114/116), 96.12% 
(99/103) and 46.93% (103/222) among  participants who received standard, 1/10th, 1/100th and 
<1/100th fractional doses respectively.39  
In their 1977 study in Beckenham and Dartford, England; Freestone and colleagues allocated 30 
and 38 participants to standard and <1/100th fractional doses of the 17D yellow fever vaccine 
respectively. They found seroconversion rates (assessed at four weeks following vaccination) to 
be 100% (30/30) and 47.37% (18/38) among those who received standard and <1/100th 
fractional doses respectively.38  
In 1988, Rio de Janeiro, Brazil; Lopes and colleagues assigned 46, 49, 56, 55 and 53 military 
personnel to be vaccinated with standard, 1/10th, 1/50th, 1/100th and <1/100th doses of the 
17D yellow fever vaccine respectively. Their seroconversion rates at four weeks following 
vaccination were 100% (46/46), 100% (49/49), 85.71% (48/56), 83.64% (46/55) and  41.50% 
(22/53) respectively.35 
Roukens and colleagues in their 2008 trial in Leiden, the Netherlands, randomised 78 and 77 
participants to receive standard and 1/5th doses of the 17D yellow fever vaccine respectively. All 
(100.00%) of the participants in both standard and 1/5th vaccination arms seroconverted four 
weeks following vaccination.35  
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In 2013, Rio de Janeiro, Brazil; Martins and colleagues randomised 131, 115, 132, 131, 122 and 
118 army personnel to receive standard, 1/3rd, 1/10th, 1/50th, 1/100th and <1/100th doses of 
the 17DD yellow fever vaccine respectively. Their seroconversion rates at four weeks following 
vaccination were 97.70% (128/131), 99.13% (114/115), 97.72% (129/132), 96.95% (127/131), 
88.52% (108/122) and 57.69% (79/118) respectively.36  
In their 2014 trial, also in Rio de Janeiro, Brazil; Campi-Azevedo and colleagues randomised 157, 
144, 150, 140, 145 and 149 army personnel to receive standard, 1/10th, 1/3rd, 1/50th, 1/100th 
and <1/100th doses of the 17DD yellow fever vaccine respectively. Those who seroconverted 
after four weeks were 98.09% (154/157), 100.00% (144/144), 98.00% (147/150), 97.14% 
(136/140), 88.97% (129/145) and 57.05% (85/149) respectively.34  
Table 3: Seroconversion rates in individual studies 
Study Seroconverted Total vaccinated Seroconversion rate (95% CI) 
Fox 1943 Standard dose 109 109 100.00 (96.67 – 100.00) % 
1/10th dose 114 116 98.28 (93.91 – 99.79) % 
1/100th dose 99 103 96.12 (90.35 – 98.93) % 
<1/100th dose 103 222 46.39 (39.67 – 53.19) % 
Freestone 1977 Standard dose 30 30 100.00 (88.43 – 100.00) % 
<1/100th dose 18 38 47.37 (30.98 – 64.18) % 
Lopes 1988 Standard dose 46 46 100.00 (92.29 – 100.00) % 
1/10th dose 49 49 100.00 (92.75 – 100.00) % 
1/50th dose 48 56 85.71 (73.78 – 93.62) % 
1/100th dose 46 55 83.64 (71.12 – 92.23) % 
<1/100th dose 22 53 41.50 (28.14 – 55.87) % 
Roukens 2008 Standard dose 78 78 100.00 (95.38 – 100.00) % 
1/5th dose 77 77 100.00 (95.32 – 100.00) % 
Martins 2013 Standard dose 128 131 97.70 (93.45 – 99.52) % 
1/3rd dose 114 115 99.13 (95.25 – 99.97) % 
1/10th dose 129 132 97.72 (93.50 – 99.53) % 
1/50th dose 127 131 96.95 (82.37 – 99.16) % 
1/100th dose 108 122 88.52 (81.49 – 93.58) % 
<1/100th dose 79 118 66.95 (57.69 – 75.33) % 
Campi-Azevedo 
2014  
Standard dose 154 157 98.09 (94.51 – 99.60) % 
1/3rd dose 144 144 100.00 (97.47 – 100.00) % 
1/10th dose 147 150 98.00 (94.27 – 99.59) % 
1/50th dose 136 140 97.14 (92.84 – 99.22) % 
1/100th dose 129 145 88.97 (82.70 – 93.56) % 
<1/100th dose 85 149 57.05 (48.69 – 65.12) % 
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4.5.1.2. Meta-analyses of seroconversion rates 
Since included studies involved multiple intervention arms with varying dilutions of the standard 
doses, we stratified meta-analyses by fractional dose strength. This helped to homogenise 
comparison across study arms between similar strengths of fractional doses and their 
corresponding standard doses. Apart from dealing with heterogeneity across vaccine arms, 
stratification also enabled stratum-level reporting of immunogenicity estimates for each stratum, 
thereby helping to deal with the unit of analyses error that could have resulted from double-
counting of control groups across strata, if they were all pooled in a single meta-analysis.52 
Two studies compared immunogenicity between 1/3rd fractional doses and the standard doses 
of the reference vaccine lots, with a combined sample size of 557 (259 in the intervention arms 
and 288 in the control groups).34 36 Seroconversion rates of 1/3rd fractional doses compared with 
the reference standard doses were respectively 99.13% (114/115) and 97.71% (128/131) in 
Martins 201336; and 100.00%(144/144) and 98.09% (154/157) in Campi-Azevedo 2014.34 
Combining data from the studies shows that there was no statistically significant difference in 
immunogenicity between 1/3rd and reference standard doses (two trials, 547 participants: RR 
1.02, 95% CI 1.00 to 1.04, I2= 0 %) (Figure 2 and Table 4). 
One study, Roukens 2008, compared between 1/5th fractional dose and the standard dose 
among 77 participants in the intervention arm and 78 in the control group.35 They reported 
seroconversion rates of 100.00% in both fractional and standard dose vaccine arms (77/77 and 
78/78 respectively), showing that there was no statistically significant difference in 
immunogenicity between 1/5th and standard doses (one trial, 155 participants: RR 1.00, 95% CI 
0.98 to 1.03) (Figure 2 and Table 4). 
Four studies compared immunogenicity between 1/10th and standard doses of the reference 
vaccine lots, with a combined sample size of 890 (447 and 443 in the intervention and control 
arms respectively).34 36 37 39 Seroconversion rates of 1/10th fractional doses compared with the 
reference standard doses were respectively 98.28% (114/116) and 100.00% (109/109) in Fox 
194339; 100.00% (49/49) and 100.00% (46/46) in Lopes 1988 37; 97.73% (129/132) and 97.71% 
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(128/131) in Martins 201336; and 98.00% (147/150) and 98.09% (154/157) in Campi-Azevedo 
2014.34 Combining data from the studies shows that there was no statistically significant 
difference in immunogenicity between 1/10th fractional doses and reference standard doses 
(four trials, 890 participants: RR 0.99, 95% CI 0.98 to 1.01, I2= 0 %) (Figure 2 and Table 4). 
Three studies compared immunogenicity between 1/50th and standard doses among 661 
participants (327 in the intervention arms and 334 in the control arms).34 36 37 The first study, 
Lopes 1988, reported seroconversion rates of 85.71% (48/56) and 100.00% (46/46) 
seroconversion rates in the 1/50th fractional dose and standard dose arms respectively.37 The 
second study, Martins 2013, reported 96.95% (127/131) and 97.71% (128/131) while the third 
study, Campi-Azevedo 2014 reported 97.14% (136/140) and 98.09% (154/157) in the 1/50th 
fractional dose and standard dose vaccine arms respectively.34 Combining data from the studies 
shows that there was no statistically significant difference in immunogenicity between 1/50th 
fractional dose and reference standard doses (three trials, 661 participants: RR 0.97, 95% CI 0.92 
to 1.02, I2= 72 %) (Figure 2 and Table 4). The substantial between-study heterogeneity observed 
was driven by the Lopes 1988 study, as explored and described later in sensitivity analyses. 
Immunogenicity of lower fractional doses was also investigated. Four studies compared 
immunogenicity between 1/100th fractional doses and the standard doses of the reference 
vaccine lots, with a combined sample size of 868 (425 and 443 in the intervention and control 
arms respectively).34 36 37 39 Seroconversion rates of 1/100th fractional doses compared with the 
reference standard doses were respectively 96.12% (99/103) and 100.00% (109/109) in Fox 
194339; 83.64% (46/55) and 100.00% (46/46) in Lopes 198837; 88.52% (108/122) and 97.71% 
(128/131) in Martins 201336; and 88.96%(129/145) and 98.09% (154/157) in Campi-Azevedo 
2014.34 Combining data from the studies shows a statistically significant lower immunogenicity 
of the 1/100th fractional dose, compared with the reference standard doses (four trials, 868 
participants: RR 0.92, 95% CI 0.87 to 0.97, I2= 60 %) (Figure 2 and Table 4). The moderate 
between-study heterogeneity observed was driven by the Fox 1943 study, as explored and 
described later in sensitivity analyses. 
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Much lower fractional doses were also investigated. Five studies investigated the comparative 
immunogenicity between <1/100th fractional doses and standard doses of the reference vaccines 
among 1053 participants (580 and 473 in the intervention and control arms respectively).34 36-39 
Seroconversion rates of <1/100th fractional doses compared with the reference standard doses 
were respectively 46.40% (103/222) and 100.00% (109/109) in Fox 194339; 47.37% (18/38) and 
100.00% (30/30) in Freestone 197738; 41.51% (22/53) and 100.00% (46/46) in Lopes 198837; 
66.95% (79/118) and 97.71% (128/131) in Martins 201336; and 57.05% (85/149) and 98.09% 
(154/157) in Campi-Azevedo 2014.34 Combining data from the studies shows a statistically 
significant lower immunogenicity of the <1/100th fractional doses, compared with the reference 
standard doses (five trials, 1053 participants: RR 0.53, 95% CI 0.44 to 0.64, I2= 80 %) (Figure 2 and 
Tables 4). The considerable heterogeneity observed was mostly driven by the Fox 1943 study, as 
explored and described later in sensitivity analyses. 
Overall, the results of the meta-analysis show that immunogenicity did not differ between 
participants who received 1/3rd, 1/5th, 1/10th and 1/50th fractional doses, compared with those 
who received the standard doses of the reference vaccines, with no substantial heterogeneity 
between studies. However, there was statistically significant lower immunogenicity in fractional 
doses lower than 1/50th (1/100th and <1/100th), compared with the reference standard dose 
vaccine. We assessed the certainty of the evidence across fractional dose arms using the Grading 
of Recommendations, Assessment, Development and Evaluation (GRADE) approach. Though 
evidence from randomised trials is considered of high certainty in the GRADE framework; we 




Figure 2: Forest plot showing seroconversion rates of fractional doses of the yellow fever 
vaccine compared to standard doses of the vaccine 
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Table 4: Comparative immunogenicity stratified by strength of fractional doses 
 




 Standard dose Fractional dose (studies) 
Standard vs 1/3rd 
doses 
282 / 288; 97.92 (95.52 – 99.23) % 258 / 259; 99.61 (97.87 – 99.99) % RR 1.02  
(1.00 to 1.04) 
547 
(2 studies) 
Standard vs 1/5th 
doses 
78 / 78; 100.00 (95.38 – 100.00) % 77 / 77; 100.00 (95.32 – 100.00) % RR 1.00 
(0.98 to 1.03) 
155 
(1 study) 
Standard vs 1/10th 
doses 
437 / 443; 98.65 (97.08 – 99.50) % 439 / 447; 98.21 (96.50 – 99.22) % RR 0.99 
(0.98 to 1.01) 
890 
(4 studies) 
Standard vs 1/50th 
doses 
328 / 334; 98.20 (96.13 – 99.34) % 311 / 327; 95.11 (92.18 – 97.18) % RR 0.97 





437 / 443; 98.65 (97.08 – 99.50) % 382 / 425; 89.88 (86.61 – 92.58) % RR 0.92 





467 / 473; 98.73 (97.26 – 99.53) % 307 / 580; 52.93 (48.78 – 57.06) % RR 0.53 





4.5.1.3. Subgroup analyses of seroconversion rates 
4.5.1.3.1. Subgroup analyses of seroconversion rates by vaccine sub-strain 
When grouped according to the constituent viral sub-strain of the vaccines, immunogenicity of 
≥1/50th doses did not differ across vaccine sub-strains (six trials, 1631 participants: RR 0.99, 95% 




Figure 3: Subgroup immunogenicity of fractional doses of the yellow fever vaccine by vaccine sub-strain 
 
 
4.5.1.3.2. Subgroup analyses of seroconversion rates by geographical region 
When grouped by continents, immunogenicity of ≥1/50th doses did not differ across vaccine sub-




Figure 4: Subgroup immunogenicity of fractional doses by region/endemicity 
 
4.5.1.4. Sensitivity analyses of seroconversion rates 
The sensitivity analysis confirmed the robustness of pooled estimates. When excluding individual 
studies, the 95% confidence intervals of risk ratios maintained the absence of significant 
differences between standard, 1/5th and 1/10th fractional doses (95% CI lower limit ranged from 
0.95 to 0.98; upper limit ranged from 1.01 to 1.05); while also maintaining observed differences 
between standard and 1/100th and <1/100th fractional doses (95% CI lower limit ranged from 
0.35 to 0.76; upper limit ranged from 0.67 to 0.95). When restricting the comparison of the 
1/50th dose to the Lopes 1988 study alone, 1/50th dose became significantly less immunogenic 
than the standard dose, contrary to the earlier pooled effect of non-inferiority. When restricting 
the analysis to studies with low risk of bias; selection bias and post-vaccination attrition of >25% 
did not substantially influence the pooled estimates between standard and 1/3rd, 1/10th and 
1/50th fractional doses (95% CI lower limit ranged from 0.95 to 0.98; upper limit ranged from 
1.01 to 1.05) and between standard and 1/100th and <1/100th fractional doses (95% CI lower 
limit ranged from 0.40 to 0.88; upper limit ranged from 0.73 to 0.99). 
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4.5.1.5. Antibody geometric mean titres 
Of the six studies included, actual antibody Geometric Mean Titres (GMT) values were reported 
in three studies.36-38 Due to variation in the units in which GMTs were expressed across studies, 
they could not be pooled and meta-analysed. Freestone 1977 reported no difference in antibody 
geometric mean titres across vaccine arms, with titres of 2.74 – 29.6 and 2.97 – 3.10 neutralising 
index (N.I) in standard and <1/100th fractional dose vaccine arms respectively.38 Similarly, Lopes 
1988 found no significant difference in antibody titres among participants who received different 
vaccine doses; 1656, 1955, 1778, 1636 and 1940 PFU/dose in standard, 1/10th, 1/50th, 1/100th 
and <1/100th doses respectively.37  However, Martins 2013 demonstrated an incremental relation 
between vaccine doses and antibody titres among participants who received different vaccine 
doses; 13,479 mIU/mL, 12,191 mIU/mL, 11,608 mIU/mL, 12,145 mIU/mL, 6,837 mIU/mL, 1970 
mIU/mL in standard, 1/3rd, 1/10th, 1/50th, 1/100th and <1/100th doses respectively.36 
4.5.2. Adverse events following vaccination 
Three of the six included studies assessed vaccine safety.35 36 38 Freestone 1977 reported 
headache, redness and pain at the site of vaccinations as the most common adverse events, with 
no significant difference in occurrence between vaccine arms.38 Roukens 2008 assessed 
participants for self-reported adverse events following vaccination, their duration and severity 
using in a 32-week diary. They found that fractional dose vaccination evoked itching, redness and 
swelling at the site of inoculation more frequently and for a significantly longer period than after 
standard dose vaccination. Longer pain and myalgia at the site of injection were more frequently 
reported in the standard dose arm. The severity of adverse events did not reveal a difference in 
experienced discomfort (both local and systemic) between the fractional and standard dose 
vaccine arms.35 Martins 2013 assessed safety  using self-reported adverse events diaries during 
the first 10 days after vaccination. Headache and fatigue were the most frequent symptoms 
(reported by more than 20% of participants). The only statistically significant difference was more 
frequent injection-site pain in the standard dose group (21.3%) compared with 1/3rd (11.3%), 
1/10th (12.0%), 1/50th (13.3%), 1/100th (10.1%) and <1/100th (9.3%) in the fractional dose 
vaccine arms.36 Of note is that none of the three studies reported any serious adverse events 
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following vaccination across any of the vaccine arms. Considering the limited details of safety 
findings, we were unable to appraise and standardise reported adverse events using the Brighton 
Collaboration case definitions.24 26 29-32. For the same reason, we are uncertain whether there are 
differences between standard and fractional doses of yellow fever vaccines in the incidence of 
severe adverse events following vaccination (very low certainty evidence, table 5). 
4.5.3. Secondary outcomes 
None of the included studies reported data on incidence of yellow fever and mortality. 
Table 5: GRADE summary of findings for the effects of fractional dose yellow fever vaccine 
Population: Healthy, immunocompetent adults 
Settings: Latin America (endemic) and Europe (non-endemic) 
Intervention: Vaccination with fractional doses of yellow fever vaccine 
Comparison: Vaccination with the standard yellow fever vaccine 






(GRADE)  Standard dose Fractional dose (studies) 
seroconversion rates; 
Standard vs 1/3rd doses  
98 per 100 (96 to 99) 100 per 100 (98 to 100) RR 1.02  







Standard vs 1/5th doses 
100 per 100 (95 to 100) 100 per 100 (95 to 100) RR 1.00 







Standard vs 1/10th doses 
99 per 100 (97 to 100) 98 per 100 (97 to 99) RR 0.99 







Standard vs 1/50th doses 
98 per 100 (96 to 99) 95 per 100 (92 to 97) RR 0.97 







Standard vs 1/100th doses 
99 per 100 (97 to 100) 90 per 100 (87 to 93) RR 0.92 







Standard vs <1/100th doses 
99 per 100 (97 to 100) 53 per 100 (49 to 57) RR 0.53 






Serious adverse events 
following vaccination 





CI: Confidence interval; RR: Risk ratio; GRADE: Grading of Recommendations Assessment, Development and Evaluation. 
1 Downgraded by 1 level (from high), because one of the studies has a high risk of attrition bias. 
2 Downgraded by 1 level, because it involves only one study with small sample size. 
3 Downgraded by 1 level, because one of the studies has a high risk of selection bias and another study has a high risk of attrition bias. 
4 Downgraded by 2 levels due to high risks of selection and attrition bias and inconsistency of outcomes (substantial heterogeneity 
and non-overlapping of confidence intervals) 
5 Downgraded by 2 levels due to high risks of selection and attrition bias and inconsistency (substantial heterogeneity) 
6 Downgraded by 2 levels due to high risks of selection and attrition bias, imprecision (wide confidence intervals) and inconsistency 
(substantial heterogeneity) 
7 No data reported 
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5. Discussion   
5.1. Summary of main results 
Based on six included studies representing a total of 2,371 participants, we found no statistically 
significant difference in immunogenicity between participants who received fractional doses 
containing one-third (two trials), one-fifth (one trial, 155 participants), one-tenth (four trials, 890 
participants), and one-fiftieth (three trials, 661 participants) of the standard dose and those who 
received the full standard dose. However, immunogenicity was significantly lower among 
participants who received fractional doses containing 1/100th (four trials, 868 participants) and 
<1/100th (five trials, 1053 participants) of the standard dose and those who received the full 
standard dose. Thus, these pooled estimates provide moderate certainty evidence that there is 
little or no difference in immunogenicity between ≥1/50th fractional doses and the standard dose 
of yellow fever vaccines. Adverse events following vaccination did not differ across doses and no 
serious adverse events were reported in any study arm. Due to the limited data reported, we are 
uncertain whether there are differences between standard and fractional doses of yellow fever 
vaccines in the incidence of severe adverse events following vaccination. 
 
5.2. Overall completeness and applicability of evidence 
This systematic review includes relevant primary studies meeting inclusion criteria, identified 
through comprehensive and up-to-date literature search. The few eligible studies found are an 
indication of the dearth of evidence on the topic. To the best of our knowledge, this review is the 
first to systematically and meta-analytically evaluate the effect of this intervention. Notably, the 
three earlier (1943 – 1988) studies37-39 included in the review employed immunological methods 
and vaccine dose units (plaque forming units, PFUs) different from those currently in use. In 2008, 
the World Health Organization (WHO) recommended the use of international units (IUs) for 
defining vaccine dose.33 Consequently, the three more recent (2008 – 2014) studies34-36 
expressed antibody titres and vaccine doses in international units, thereby making comparisons 
difficult across the two eras. Though the World Health Organisation recommends that the mini-
mum potency for standard dosing should not be less than 1000 international units per dose or 
its equivalent in plaque forming units 16 33, the relationship between PFUs and international units 
29 
 
of vaccine doses remains uncertain.56 57 Therefore, to address these differences and enable 
comparability across studies, we categorised reported fractional doses as corresponding to 
1/3rd, 1/10th, 1/50th, 1/100th or <1/100th of their reference standard doses and stratified meta-
analyses accordingly. 
Though this review’s findings on immunogenicity are based on assessment at the fourth or fifth 
week after vaccination, evidence suggests that duration of immunity of fractional dose 
vaccination can persist for long.35 Further research will however be needed to ascertain the long 
term immunity of fractional dose vaccination as well as clarify whether or not booster doses will 
be required in individuals who were vaccinated with fractional doses, as currently recommended 
for standard dose vaccination. As the participants in the included studies were mostly young 
adults, the findings may not be generalisable to elderly people. This is given the attendant risk of 
attenuated virus causing higher viraemia, that may result in severe disease in elderly subjects 
(age ≥60 years) who have been found to have a lower antibody response to yellow fever 
vaccines.27 28 Individuals with suppressed immunity were also not represented in the study 
populations. Therefore, with the high burden of immunosuppression (due to HIV infection or 
cancer chemotherapy), especially in yellow fever endemic settings, further investigations of the 
effectiveness of fractional dose vaccination in these specific populations are of utmost 
necessity.49 
Reported adverse events were few in the three studies that assessed vaccine safety. The non-
occurrence of serious adverse events in all the studies is consistent with documented rare 
incidence of vaccine-associated viscerotropic and neurotropic diseases (0 to 0.8 cases per 100 
000 persons vaccinated.4 These studies however have limited statistical power and follow-up 
durations to detect the occurrence of such uncommon serious adverse events. Hence, the 
findings do not permit conclusions on the safety profile of fractional dose yellow fever 
vaccination. They therefore need to be verified in larger and demographically representative 






5.3. Quality of the evidence 
Overall, the quality of evidence in this review is of low to moderate certainty. Though evidence 
from randomised trials is considered of high certainty in the GRADE framework; we downgraded 
the evidence for various reasons. Evidence from the 1/5th fractional doses was graded as 
moderate certainty evidence due to its involvement of only one study with small sample size; 
those of 1/3rd and 1/10th doses were also downgraded by one level for high risks of selection 
and attrition bias; while those of 1/50th, 1/100th and <1/100th were further downgraded for 
inconsistency of outcomes and imprecision in the studies involved. Evidence on safety was of 
very low certainty. A methodological limitation of this study is the inclusion of both randomised 
and quasi-randomised trials in the pooled estimates. A possible approach of addressing this could 
have been to down-weight quasi-randomised or adopting a Bayesian approach to pooling the 
estimates. These statistical methods are however beyond the scope of a mini-dissertation but 
could be considered for future publication of the review’s findings. 
 
5.4. Potential biases in the review process 
We followed the guidance contained in the statement on Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA). Potential biases were minimised by performing a 
comprehensive search of databases of published and grey literature, including hand searching of 
reference lists and conference proceedings. Screening of search outputs for potentially eligible 
studies, assessment of eligibility, risk of bias appraisal and data extraction were carried out in 
duplicates by two independent researchers. 
 
5.5. Agreements and disagreements with other studies or reviews   
These findings present evidence of moderate certainty, which are consistent with those of two 
previous narrative literature reviews16 33 and observational studies40-42 which demonstrated that 
fractional dose vaccination was highly immunogenic and safe. The equivalent immunogenicity of 
yellow fever vaccines from the 17D and 17DD vaccine sub-strains demonstrated by the subgroup 




6. Authors’ conclusions 
6.1. Implications for practice 
With future yellow fever outbreaks likely to require additional immunisation campaigns at large 
scale and further straining limited global stockpile of the yellow fever vaccine, the findings of this 
review support the use of fractional dosing as a dose-sparing strategy for yellow fever 
vaccination. There is some evidence of the long-term duration of immunity following fractional 
dose vaccination, with a recent study showing that 85.2% of participants remained seropositive 
eight years after initial vaccination with fractional doses as low as 1/50th of the standard dose.59 
Until there is substantial evidence of longer-term immunity, however, this strategy should not 
ideally serve as long-term vaccination strategy, nor replace established routine immunisation 
practices. It does not currently meet the vaccination requirements under the International Health 
Regulations (IHR), hence proof of vaccination for international travel still requires re-vaccination 
with a standard full dose.4  The strategy is, nonetheless, particularly vital in preventive 
vaccination of large number of at-risk populations during outbreaks in densely-populated 
settings. In such situations, capacity building and training of frontline health workers and 
vaccinators on the effective handling and off-label use of the vaccine in fractional doses are 
necessary. 
Yellow fever vaccines contain no preservative, hence there is a potential risk of increased 
contamination if vials are repeatedly punctured during immunisation sessions.16 60 To address 
this concern, the use of lower-dose vials could help minimise the number of punctures, while 
reducing the risk of post-reconstitution contamination and mitigating vaccine waste. The 
variation in actual doses of yellow fever virus particles in the standard doses across all 
prequalified vaccine manufacturers presents a quality assurance challenge.56 57 This needs to be 
addressed to ensure that fractional doses of corresponding dilution strengths are similar in viral 
contents across all vaccine lots. Lastly, active post-vaccination surveillance is necessary to allow 
for assessment of duration of protection, effectiveness, tracking of break-through cases and 




6.2. Implications for future research 
This review’s findings are based on assessment of protective immunity and safety of fractional 
doses of the yellow fever vaccine in healthy, immunocompetent and mostly young adults in a 
limited number of settings. There are concerns that fractional dosing might be less effective or 
less safe in children, elderly persons and immunocompromised individuals.4 These deserve 
further research efforts. Until data relevant to such specific subgroups become available, children 
aged <2 years, pregnant women, and individuals with compromised immunity should 
preferentially be vaccinated using standard doses during preventive vaccination campaigns.  
Further research is also needed to investigate the longer-term protective immunity of fractional 
dose vaccinations as well as well as put to rest the question as to whether or not booster doses 
are required in individuals who were vaccinated with fractional doses. While available clinical 
trial data do not suggest a need for revaccination after fractional dose vaccination, there is need 
for further monitoring of immunogenicity, duration of immunity, and safety to strengthen this 
evidence.16 36 Lastly, available data on the effects of fractional dose yellow fever vaccination are 
mostly on immunogenicity and/or safety, with lack of evidence on the actual efficacy or 
effectiveness of the strategy in preventing incident yellow cases in those vaccinated. With 
efficacy studies being highly resource-intensive and in the context of resource-constraints typical 
of yellow fever endemic areas, integrating vaccine efficacy assessment into existing 
immunisation programmes and impact evaluation frameworks might be a cost-cutting approach 
to prospectively assessing the effectiveness of the strategy in large scales. 
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PART D:  APPENDICES
 




1.2. EBSCOhost (including CINAHL) 
 
Search # Search Texts and Syntaxes 
#1 Yellow Fever [MeSH Terms] 
#2 Yellow Fever Vaccine [MeSH Terms] 
#3 yellow fever vaccine OR yellow fever vaccination OR yellow fever immunization 
#4 #1 OR #2 OR #3 
#5 Dose-Response Relationship, Immunologic [MeSH Terms] 
#6 fractional dosing OR Fractionated dosing OR drug dose comparison OR sub-
dose OR sub-dosage OR reduced dose OR reduced dosing OR reduced dosage 
OR dose-sparing OR immunologic dose response relationship 
#7 #5 OR #6 
#8 safety OR adverse reaction OR adverse event OR adverse effects OR toxicity OR 
reactogenicity OR immunogenicity OR immunogenic OR immune response OR 
seroconversion OR efficacy OR effects OR effectiveness 
#9 #7 OR #8 
#10 #4 AND #9 
Search # Search Texts and Syntaxes 
S1 SU yellow fever OR SU yellow fever vaccine OR AB (yellow fever vaccine OR 
yellow fever vaccination OR yellow fever immuni#ation) 
S2 SU dose response relationship, immunologic OR AB (fractional dosing OR 
Fractionated dosing OR drug dose comparison OR sub-dose OR sub-dosage 
OR reduced dose OR reduced dosing OR reduced dosage OR dose-sparing 
OR immunologic dose response relationship) 
S3 AB safety OR adverse reaction OR adverse event OR adverse effects OR 
toxicity OR reactogenicity OR immunogenicity OR immunogenic OR immune 
response OR seroconversion OR efficacy OR effects OR effectiveness 
S4 S2 OR S3 
S5 S1 AND S4 
2 
 
 1.3. Scopus 
 
Search # Search Texts and Syntaxes 
#1 TITLE-ABS-KEY yellow Fever OR yellow fever vaccine OR (yellow fever 
vaccine OR yellow fever vaccination OR yellow fever immune?ation) 
#2 TITLE-ABS-KEY dose?response relationship, immunologic OR (fractional 
dosing OR fractionated dosing OR drug dose comparison OR sub-dose OR 
sub-dosage OR reduced dose OR reduced dosing OR reduced dosage OR 
dose-sparing OR immunologic dose response relationship) 
#3 TITLE-ABS-KEY safety OR adverse reaction OR adverse event OR adverse 
effects OR toxicity OR reactogenicity OR immunogenicity OR immunogenic 
OR immune response OR seroconversion OR efficacy OR effects OR 
effectiveness 
#4 #2 OR #3 
#5 #1 AND #4 
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Appendix 2: Data extraction tool 
 
Section 1: General review information 
Review Title: Effects of Fractional Dose Yellow Fever Vaccine: Systematic Review and Meta-analysis 
Study ID (Surname and Year: as it will appear in RevMan):  
Name of review author completing this form:  
Date form completed:  
Name of review author checking the data extracted to this form: 
Other information and notes: 
 
Section 2: Methods of the study 
Details of Study (to be reported in the Characteristics of Included Studies tables) 
Minimum standards: 
Aim of study (As stated in the trial report/s.  What was the trial designed to assess?):  
Study design:  
Number of arms or groups (including control groups); briefly describe each:  
Consumer involvement (eg. In design of study and/or intervention; in delivery of intervention; in 
evaluation of intervention; in interpretation of study findings) 
Funding source (also include any details about possible or explicit conflicts of interest):  
Informed consent obtained? (Yes/No/Unclear):  
Ethical approval (Yes/No/Unclear): 
 
Section 3: Study characteristics - Participants 
The minimum standards below outline those fields on which data must be extracted, the optional items 
can be chosen or adapted; and decisions need to be made about what to report in the Characteristics of 
included studies table and what could be reported in Additional tables.  
Author contact details for study  
Further information required  
Correspondence with authors successful or 
not; what information was received and when 
 
Will any additional unpublished data supplied 





Description (eg. Patients/consumers; carers; parents of patients/consumers; health professionals; well 
people in the community):  
Geographic location (eg. City/State/Country):  
Setting (eg. Community, home, health centre, miliary facility):  
Methods of recruitment of participants (How were potential participants approached and invited to 
participate?)  
Inclusion/exclusion criteria for participation in study:  





Study numbers Number 
Eligible for inclusion  
Excluded  
Refused to take part  
Randomised to intervention group(s)  
Randomised to control group  
Excluded post randomisation (for each group; with 
reasons if relevant) 
 
Withdrawn (for each group; with reasons if 
relevant) 
 
Lost to follow up (for each group; with reasons) Intervention group (with reasons) 
Control group (with reasons) 










Section 4: Study characteristics - Interventions 
Data on interventions (and control) procedures should be collected in enough detail to allow replication 
of the procedures. Depending on how much detail is available, some of this information might be best 
reported in Additional tables within the review, as the Characteristics of Included Studies tables will 
otherwise become very long and unwieldy.  
Data should be extracted for each relevant (included) intervention arm, as well as the control arm. 
Information on any co-interventions (if applicable) should also be recorded. 
Minimum standards: 
Item Explanation, notes  Intervention Control 
1 Intervention name Include a brief name or phrase that describes 
the intervention 
(including definition of any acronyms or 
abbreviations) 
  




Aim(s) of intervention  
(as stated in the trial report/s. What was the 
problem that this intervention was designed 
to address?)  
 
Describe any theory (with key references) or 
rationale relevant to the intervention. 
(Note that for a complex intervention with 
different components, each component may 
have a different aim or rationale) 
Describe any information on the quality of 
the intervention, assessed by study authors, 
others, or by you - such as the evidence base 
supporting the intervention. 
  





Describe the content, format(s) or media, 
source of materials (if possible, where they 
can be accessed), and any other information 
relevant to the physical or information 
materials provided to participants or in 
training providers of the intervention. 
Procedures: 
Describe each of the processes used in 
delivering the intervention (eg education, 




Note that some complex interventions 
require additional support activities to be 
implemented, and if so details of these 
should also be reported. 
Note also that some complex interventions 
require sequencing of activities, whereas for 
others the order of delivery is less critical.  
Mode of delivery: 
Describe the mode of delivery of the 
intervention, such as whether it was 
delivered face-to-face (eg in patient 
consultation, educational session, training) or 
at a distance (eg via phone, internet, mail); 
and whether the delivery was to individuals 
or groups of participants. 
Cointerventions: 
Describe the delivery of any co-interventions 
(Co-interventions may be separate to the 
intervention of interest, or they may be other 
similar elements in a suite of interventions 
which have a common purpose). 





Describe who was involved in delivery of each 
component of the intervention and/or each 
different intervention provider. 
‘Intervention provider’ could for example be 
taken to mean a health professional or it 
could mean a consumer peer advocate. 
Include description of any specific training 
given to providers to deliver the intervention, 
numbers of providers, professional 
background, specific pre-existing skills or 
experience required, quality of any specific 
training received to deliver the intervention, 
and any measures of competence or 
consistency in delivering the intervention 
recorded before or during the study. 
  




Describe the features of the setting (location) 
that might be relevant to intervention 





If the location varied this should be 
described, with relevant features that might 
affect the intervention delivery; as should any 
requisite features of the location that might 
impact on intervention delivery or feasibility  
(eg location close to participants' usual 
doctor, availability of equipment) 
7 When and how 
often or how much of 
the intervention was 
provided? 
Describe how the intervention was delivered, 
such as stages, timing, frequency, number of 
sessions, intensity and duration of 
intervention delivery. 
  




If the intervention was changed during the 
study, this should be described 
(eg unforseen modifications required, 
changes in study circumstances requiring 
modifications to the intervention). 
If such modifications happen, why, what, how 
and when the intervention was changed 
should be described. 
  






Assessment of fidelity: if intervention fidelity 
was assessed, describe the extent to which 
the intervention was delivered as intended. 
(ie the amount or type of intervention 
planned for delivery might differ from what 
was actually delivered) 
If strategies to maintain intervention fidelity 
were planned before intervention delivery, or 
were used during the study, describe these, 
along with any materials or tools used. 
  
 
**Table is adapted from Hoffman et al (2014). Better reporting of interventions: template for intervention 
description and replication (TIDieR) checklist and guide. BMJ; 348: P 1687. 
 
 
Section 5: Study characteristics - Outcomes and comparison groups 
All data reported by the included study for all eligible primary and secondary outcomes sought by the 
review must be reported. 
Data on all relevant adverse events must also be collected and reported. These should be included as 
primary outcomes, unless there is a good rationale not to do so.  
6 
 
If adverse effects are not reported by the included study, it should be clearly reported whether adverse 
effects were investigated or not by the study. 




Outcome Method of assessing 
outcome measures 
eg, phone survey, 
questionnaire 
Method of follow-up 
for non-respondents 
Timing of outcome assessment  
(including frequency, length of follow 
up)  
    




Primary outcomes - adverse events 
(eg complaints, levels of dissatisfaction, adverse incidents, side effects, increased inequities) 
Adverse event Method of assessment Timing of assessment (including 
frequency, length of follow up) 
   







Outcome Method of assessment Timing of outcome assessment  
(including frequency, length of follow up)  
   
   
7 
 
Section 6: Data and results 
These data will be used in the “Comparisons and Data” section in RevMan (not the table “Characteristics 
of Included Studies”) and as the basis for the “Results” section of your review text. All data are numbers 
(of patients/units), not percentages. 
 
Minimum standards:  
You must extract all data relevant to the outcomes specified in your selection criteria. This may be as 
dichotomous, continuous, and/ or other data or results. 
 
Dichotomous outcomes 
Outcome Timing of outcome 
assessment 
(days/months) 
Intervention group* Control group Notes 
Observed 
(n) 




       
       
 

























         
         
         
